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ABSTRACT
There is currently a critical health issue of global concern; there are many types of
bacterial pathogens that have evolved a resistance to many common, conventional
antibiotics. In silico structural tools can be used to identify antimicrobial peptide
(AMP) sequence modifications that result in better antibacterial therapeutics without
increasing human erythrocyte hemolysis. Out of the five AMPs designed for this
Thesis project, two were minor modifications of an existing Pleurocidin-Dermaseptin
(P-DER) hybrid sequence. The in silico structural design strategies were used to
determine on a biophysical level what made P-DER so effective. The tools included
the Chou-Fasman secondary structure algorithm, the Edmondson helical wheel model,
and the Hopp-Woods hydrophilicity scale. These design insights were used to model
the remaining three AMPs. These novel, hybrid AMPs were created by combining the
N-terminal region from CEME with the entire sequences of three other AMPs:
Ranatuerin 6, VesCP-M and Temporin. Although all five hybrid peptides were
synthesized, only the modified P-DER sequences were purified and characterized.
The AMPs were tested by varying the concentration of each peptide in contact with
the bacteria or human red blood cells (RBC). The dose-dependant cytotoxic and
hemolytic effect of those peptides on cells was determined. Screening for bacterial
growth inhibition was performed in vitro against two species each of representative
gram positive and gram negative bacteria. These tests on the AMPs were to see if it
was active against a broad spectrum of microbial pathogens that have diverse types of
cell surfaces, with the caveat that these AMPs are not suitable for therapeutic use if
they cause significant human RBC hemolysis.
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CHAPTER 1
INTRODUCTION
There is an ever growing need to develop new types of drugs that can inhibit or kill
antibiotic-resistant bacterial pathogens. Antimicrobial peptides (AMPs) are
potentially part of the answer (Jiang et al, 2011). Antimicrobial peptides are short
proteins that are naturally secreted by many organisms as part of the host defense
system against bacteria, fungi, viruses and eukaryotic parasites. The search for
undiscovered natural AMP sequences and the development of synthetic AMP analogs
has become urgent due to the emergence of resistance to conventional antibiotics by
many species of microscopic pathogens (Toke, 2005). In vertebrates, they form a
portion of the innate immune system and can be secreted constitutively or when
triggered by a specific stimulus. For a variety of reasons, antimicrobial peptides are
seen by many microbiologists as an attractive alternative to the chemically unique
antibiotics (Zasloff, 2002).

Conventional antibiotics typically act on one specific

bacterial structural or metabolic process; this gives the bacterial pathogens a pathway
to evolve around the drug (Jiang et al, 2011). In addition, novel antibiotics are
becoming much more expensive to develop and market, and there has been a
measurable decline in how many are created annually (Vicente et al, 2006). In
contrast, many AMPs, regardless of chirality, target a general bacterial structure rather
than a specific weak point; this makes it more difficult for pathogens to evolve
resistance (Toke, 2005). Many AMPs have a wide range of activity against many
pathogenic species, yet do not significantly damage host cells; this is likely due to key
structural differences in target cell surfaces. Cationic AMPs are attracted to negatively
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charged bacterial cell membrane, and cell wall components; the negative charges are
used to chelate divalent cations vital to bacterial metabolism. Many cationic AMPs
have the ability to reach and disrupt the cell membrane (Toke, 2005). Many AMPs
can additionally cause bacterial cell leakage by forming pores or by disrupting the cell
membrane via a membrane coating and destabilization (Zasloff, 2002). Developing
new AMP analogs is straightforward because they are polypeptides, and are amenable
to automated synthesis. Furthermore, AMPs will not persist in the environment, due to
the ubiquity of proteolytic enzymes (Yount et al, 2006). Each novel AMP studied is
derived from well known, naturally occurring sequences that are demonstrably active
antimicrobial peptides. A common design strategy is based on combining the strongly
amphipathic, aromatic amino acid containing, N-terminal region from one sequence
with the more hydrophobic C-terminal sequence from other naturally occurring
sequences (Boman et al, 1989).
Initially, a strongly antimicrobially active, artificial hybrid peptide called P-DER
combined the N-terminal region of a winter flounder AMP called Pleurocidin, and the
C-terminal region of a frog AMP called Dermaseptin (Jia, 2000; Cole, 1996). P-DER
was selected as a prototype peptide as it had shown impressive results in killing a wide
variety of bacterial species at therapeutic doses (Jia, 2000). The P-DER sequence was
modified to generate novel sequences. Before the novel variants were synthesized, PDER was analyzed by three in silico tools to determine the important properties of this
peptide; these characteristics included the secondary structure, alpha helical
amphipathic propensity, and hydropathic character.

2

Table 1: Antimicrobial Sequence design. The first seven antimicrobial peptide
sequences were derived from nature. The two listed extant hybrids were made by
other research labs. The last five hybrid sequences were novel designs.
Categories
Natural AMPs

Extant Hybrids
Novel Hybrids

Names

Sequences

Cercropin A:
Dermaseptin:
Melittin:
Pleurocidin:
Temporin A:
Ranatuerin 6:
VesCP-M:
CEME:
P- DER:

H-KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK-OH
H-ALWKTMLKKLGTMALHAGKAALGAAADTISQTQ-OH
H-GIGAVLKVLTTGLPALISWIKRKRQQ-OH
H-GWGSFFKKAAHVGKHVGKAALTHYL-OH
H-FLPLIGRVLSGIL-NH2
H-FISAIASMLGKFL-NH2
H-FLPIIGKLLSGLL NH2
H-KWKLFKKIGIGAVLKVLTTGLPALIS-OH
H-ALWKTMLKKAAHVGKHVGKAALTHYL-NH2
H-ALWKTMLKKAAHVGGHVGKAALTHYLN-NH2
H-ALWKTMLKKAAHVGKHVGKAALTHYLN-NH2
H-FISAIASMLGKFLKWKLFKK-NH2
H-FLPLIGRVLSGILKWKLFKK-NH2
H-FLPIIGKLLSGLLKWKLFKK-NH2

LM7-1:
LM7-2:
LM7-3 [Rana6-CEME]:
LM7-4 [Temp-CEME]:
LM7-5 [VesCP-CEME]:

Five novel hybrid sequences are shown in Table 1. All the in silico designed
peptides displayed broad enough structural transitions to be considered worthwhile to
pursue. P-DER was then altered, which produced two novel hybrid sequences called
LM7-1 and LM7-2. To create LM7-1, one residue (Lys14 → Gly14) was substituted to
increase flexibility at the hinge region and an N-terminal amide group was added to
reduce hemolytic activity. The more conservative LM7-2 only had the N-terminal
amide added. The entire sequences of Ranatuerin 6, Temporin A, and VesCP-M were
combined with part of the sequence of CEME to make novel sequences LM7-3,
LM7-4, and LM7-5, respectively.
The Chou-Fasman algorithm predicted that both LM7-1 and LM7-2 had a
noteworthy hinge region, or break, between alpha helical segments. Evidence
suggested that there should be a short, unstructured, flexible hinge between the
N-terminal and C-terminal domains, to provide an ideal place for linking distinct
segments in the proposed hybrids. The hinge is important, because a completely
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α-helical AMP has difficulty impairing bacterial growth (Scotts, 1999; Andreau,
1992). In all five of the novel peptides, the free acidic group at the C-terminal end of
the peptide was converted into an amide group; in many cases, this modification
increased the antimicrobial activity (Strandberg, 2007).
LM7-1 through LM7-5 were all produced via Solid Phase Peptide Synthesis
(SPPS). Due to time constraints, only LM7-1 and LM7-2 were further studied for this
thesis project. The AMPs were purified using gel filtration chromatography, and
preparative reversed phase high performance liquid chromatography (RP-HPLC).
Both AMPs were characterized by liquid chromatography-electrospray ionizationmass spectrometery (LC-ESI-MS). However, due to equipment deficiencies, only
LM7-1 was massed using matrix-assisted laser desorption ionization mass
spectrometry (MALDI-MS) during peptide purification. Each peptide was tested for
inhibitory activity against growth of various pathogenic gram-positive and gramnegative bacteria; the assay determined if the novel peptides were broad spectrum
active against microbial pathogens that had different types of cell surfaces. By
varying the concentrations of each peptide in contact with the bacteria, the dosedependent cytotoxic effects of these peptides were determined. As significant RBC
hemolysis is a common undesirable side-reaction of many highly active AMPs (like
Melittin), LM7-1 and LM7-2 were also tested for hemolysis of human erythrocytes
(RBCs).
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CHAPTER 2
REVIEW OF LITERATURE
Introduction
Antimicrobial Peptides (AMPs) are diverse, multifunctional components of innate
vertebrate immunity. To examine the relevance of AMPs to the Thesis project, this
review will be divided into three main strands. The first strand covers features
common to antimicrobial peptides, where they are naturally found, and their mode of
action. The second strand covers key insights into aspects of hybrid AMP structure
and design that led to the formation of the Thesis project. The third strand discusses
the specific in silico tools used to design the novel AMP sequences. Using these
guidelines can improve the design of hybrid, short, alpha-helical, cationic,
antimicrobial peptides.
2.1 Antimicrobial Peptide Overview
2.1.1 Antimicrobial Peptide Structure and Pathogenic Targets
These polypeptides form a variety of structural classes: alpha helical, beta sheet,
unstructured, and residue rich varieties. Each class has a characteristic shape and
amino acid composition: alpha helices form coils, beta sheets form switchbacks,
unstructured have a random 3D configuration, residue rich peptides are enriched with
combinations of residues that form wedges or polyproline helices. (Yount et al, 2006).
Although AMPs may share some slight structural similarities, the structures of
vertebrate AMPs are not closely related to those of invertebrate and microbial AMPs.
There is an enormous diversity of these peptides for two major reasons: there is a large
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evolutionary distance between AMPs expressed in different kingdoms, and many
AMPs in the same organism have only subtle sequence differences between each
other. Although the peptide sequence can vary considerably within these classes of
AMPs, there are closely conserved regions that are vital to each classes’ function,
alongside regions that show considerable sequence variation (Lai and Gallo, 2006).
AMPs can be active against a wide variety of pathogens: gram positive bacteria,
gram negative bacteria, protists, fungi and viruses. AMPs serve as a vital part of all
mammalian immune systems. In many cases, they are secreted in response to the
initial stages of an infection. Many AMPs are immunoattractive as well as
antimicrobial, so they play dual roles in organism defense systems. AMPs check
pathogenic growth until other immune system responses kick in, and augment an
organism’s ability to clear infections (Lai and Gallo, 2009).

2.1.2 Alpha-Helical Antimicrobial Peptide Mode of Action
The typical antimicrobial peptide mode of action is to disrupt bacterial cell
membranes, and selectively inhibit pathogen growth. Cationic, alpha-helical peptides
have a number of positively charged residues (typically 4-10 lysine or arginine
residues), which helps to attract them to elements of negatively charged bacterial cell
walls (Yount et al, 2009). The cell wall components of the bacterial cells include:
lipopolysaccharides in gram negative species (Figure 1), and teichoic acids
in gram positive species (Figure 2). Once AMPs get past the cell wall and
directly interact with the lipid bilayers, many disrupt cell membrane functions, trigger
efflux of cellular fluids, and cause eventual cell death. The few known AMPs that do
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not act by membrane disruption have a mode of action that involves either impairing
cellular enzymes or binding to genetic elements. Unlike conventional antibiotics that
target a specific bacterial cellular mechanism, AMPs generally target the overall
structures of the bacterial cell membranes. As a consequence, bacteria can more easily
evolve resistance mechanisms to get around conventional antibiotics, rather than
AMPs; this is another reason AMP research is so vital (Lai and Gallo, 2006). Part of
bacterial susceptibility to AMPs is that their cell membranes feature anionic
phospholipids, as shown in Figure 3, such as Cardiolipin (CLP), and
Phosphotidylglycerol (PG). In contrast, eukaryotic membranes feature zwitterionic or
neutrally charged phospholipids, largely Phospatidylcholine (PC), Phosphotidylserine
(PS), and Phosphatidylethanolamine (PE). These latter structures are less susceptible
to AMP binding (Yount et al, 2006).

Figure 1: Generalized Lipopolysaccharide Structure in Gram negative Bacteria.
Lipopolysaccharides (LPS) are structural polysaccharides anchored in the outer
membrane of gram negative Bacteria, facing in the extracellular direction. LPS is
composed of 3 main components: The Lipid A subunit, which is comprised of the fatty
acid tail and glucosamine carbohydrate; an invariant Core Polysaccharide region
containing phosphate groups; an O-specific polysaccharide outer portion that includes
variably repeating polysaccharide chains.
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Figure 2: Glycerol Teichoic Acid Structure in Gram Positive Bacteria. Teichoic
acids are important chelating polysaccharides found in the cell wall of gram positive
bacteria. They are composed of alternating phosphate groups, and sugars with amino
acid side chains.

Figure 3: Phospholipid Structures. Phospholipids are found in all living cells as
components of the cell membrane. All have fatty acid tails attached to a glycerol
sugar that also links to a head group via a phosphate group. The examples are
Cardiolipin (CLP), Phosphotidylglycerol (PG), Phosphotidylcholine (PC),
Phosphatidylserine (PS), and Phosphotidylethanolamine (PE).
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One of the central problems in antimicrobial peptide design is that increasing the
amphipathicity of the candidate peptides tends to increase their antimicrobial activity
at the same time it increases overall peptide affinity to a broader range of cells. This
alteration can lead to hemolysis if the AMPs contact red blood cells. Figure 4 shows
the manner by which AMPs induce leaks in bacterial cell membranes, which are
hypothesized to be through one of three mechanisms. (A) is the uncommon aggregate
pore formation, which forms multimer channels. (B) is the common carpet model
arrangement in the bacterial cell membrane, which disrupts the integrity of the
bacterial membrane. (C) is the mangainin specific torroidal pore formation, which
bends the membrane open (Yount et al, 2006).
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Figure 4: AMP Bacterial Membrane Attack Models. A) Aggregate Pore
Model: unstructured AMPs form α-helices in the cell membrane, and aggregate to
form multimeric pores. B) Carpet Model: unstructured AMPs form α-helices in the
cell membrane and destabilize the cell membrane. C) Torroidal Pore Model:
unstructured AMPs form α-helices in the cell membrane and pull the bilayer open.
Within the Alpha helical category of AMPs, the Dermaseptin class also features a
characteristic hinge region in the middle of the sequence (highlighted in red):
H-AKWKTMLKKLGTMALHAGKAALGAADTISQGTQ-OH.

The hinge region likely exists

because it increases alpha helical flexibility, which potentially allows the peptide to
slip through the cell walls of bacteria and contact the inner cell membrane. All of the
structural features of AMPs serve important functional roles, as these sequences
evolved under selective pressure over long periods of time. As a consequence,
excessive tampering with those features can lead to a loss of antimicrobial activity.
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Another important property related to conformational flexibility, is that active
antimicrobial peptides tend to form stable amphipathic alpha helices only when they
contact bacterial cell membranes (Yount et al, 2006). Folding is initiated when the
hydrophobic amino acid side chains in the peptide insert into the membrane with the
hydrophilic face of the peptide pointing back towards the aqueous extracellular
environment and the phospholipid head groups (Cole, 1996).
Amphipathic peptides, such as Dermaseptin S, commonly bind sideways on the
membrane surface, with a Tryptophan-containing N-terminal region that dips further
into the bacterial cell membrane than the C-terminal region. Dansylating the peptide
allows spectroscopic studies to be performed using fluorescent emission from the
membrane-bound peptide. In the case of dansylated Dermaseptin S, an AMP
orientation parallel to the cell membrane was indicated by a blue-shifted emission
spectrum. This peptide orientation is consistent with the “carpet” mechanism (Yount
et al, 2006).
Multiple AMPs have the ability to increase the permeability of bacterial
membranes. By having strongly cationic sequences, the AMPs are selective towards
negatively charged bacteria cell membranes, rather than neutrally charged eukaryotic
membranes. The main Eukaryotic exception is red blood cell membranes, which
contain more anionic phospholipids. The effort to design hybrid peptides that inhibit
bacterial growth without being toxic to erythrocytes is a major goal of improved
peptide designs (Toke, 2005). Forming a strong amphipathic alpha helix in solution
also increases an AMP’s hemolytic potential; one example showed that selective
interference with the regular amphipathic profile of Pardaxin and Melittin abolished
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their hemolytic potentials without diminishing their antibacterial activities (Toke,
2005).
2.2 Designing Hybrid Cationic Alpha Helical Antimicrobial Peptides
2.2.1 Prior Research into Hybrid Cationic Alpha Helical Antimicrobial Peptides
The antimicrobial peptide CEME was designed and synthesized by Boman et al.
Their study indicated that the moth AMP Cecropin, had low hemolytic potential, but
its antimicrobial activity was too weak to be therapeutically useful. At the same time,
they noted that Melittin, a bee venom component, was an extremely hemolytic and
amphipathic α-helical peptide. It was also a potent antimicrobial agent as bee venom
has evolved to be toxic to the target organism by causing tissue damage and swelling.
The Boman group decided to experiment with novel hybrid sequences that combined
selectivity-type elements of the moth Cecropin sequence, and potency-type elements
of the bee venom Melittin sequence. This was done so that they could potentially
harness the potency of Melittin to enhance the antimicrobial activity of Cecropin
without having as high a hemolytic potential as Melittin. Under the right conditions,
the new hybrid, CEME, proved to be more active than Cecropin itself (Boman et al,
1989).
Boman et al assembled a variety of hybrids by mixing and matching varying
lengths of Cecropin and Melittin sequences in different arrangements, to arrive at the
best combination. Eventually they hit upon an ideal hybrid AMP that had the
antimicrobial activity of Melittin without damaging red blood cells. The innovation
was that instead of taking a native AMP sequence and changing one residue at a time
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to improve its therapeutic properties, they joined larger segments taken from two
different, naturally occurring AMP sequences. This highly successful approach was
used to design hybrid AMPs, evaluate them using in silico tools for structural
characteristics common to the active peptides, and synthesize and test them. (Boman
et al, 1989).
Dermaseptin was one of the two sequences used to make a novel Dermaseptin and
Pleurocidin AMP called P-DER; this hybrid AMP was the starting point of the Thesis
research. Dermaseptin itself was first isolated and characterized as part of a mixture
of AMPs found in the skin and skin secretions of Xenopus frogs. Mor et al took skin
samples, homogenized them, and extracted the mixture of compounds with 10% acetic
acid. They then subjected the mixture to three rounds of chromatography (gel
filtration, ion exchange and reversed phase HPLC). Groups of already known
amphibian AMPs found in their samples included the Bominins and Magainins. They
also discovered a novel sequence that wasn’t in any of the known groups. The
sequence of Dermaseptin was determined using the N-terminal Edman degradation
method: H-AKWKTMLKKLGTMALHAGKAALGAAADTISQGTQ-OH. They compared the
Edman-derived sequence to the ratios of free amino acids yielded by acid hydrolysis,
and found the amino acid composition data was compatible between both methods.
They termed the novel AMP Dermaseptin. They purified and determined the
molecular weight of the isolated AMP using Fast Atom Bombardment-Mass
Spectroscopy as 3455.4 [m+H]+; they also determined the AMP had no special Nterminal, C-terminal or side chain modifications. Later, they chemically synthesized
the peptide using the Fmoc-type solid phase peptide synthesis (SPPS) method; they
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used three rounds of chromatography (gel filtration, ion exchange and reversed phase
HPLC) to purify the synthetic product. They demonstrated that the synthesized
Dermaseptin was identical to the isolated version in chromatographic properties, mass,
and amino acid sequencing results. By varying the hydrophobicity of the solvent,
during a Circular Dicroism Spectrometer measurement run, it was found that the
peptide favored an alpha-helix conformation in more hydrophobic environments (Mor
et al, 1991). They demonstrated the antimicrobial activity of synthetic Dermaseptin
by reporting its Minimum Inhibitory Concentration (MIC) against E.coli (1.0 μg/ml),
E.faecalis (5.0 μg/ml), and S.aureus (5.0 μg/ml); 100% hemolysis at 1 hour was
determined to be 70.0 μg/ml. Dermaseptin is a potent and potentially useful
therapeutic AMP (Mor et al, 1994).
Pleurocidin was the other sequence chosen to make the P-DER hybrid peptide, due
to its broad spectrum activity, as well as its forming an alpha-helical secondary shape
after contact with a membrane. Pleurocidin was part of a mixture of AMPs found in
the skin mucosal secretions of the winter flounder, Pleurocidin americanus. Cole et al
took the skin and mucous samples, extracted the compounds with 10% acetic acid,
centrifuged them, and subjected the mixture to two rounds of chromatography (gel
filtration, and reversed phase HPLC). After each purification round, they tested the
various fractions for antimicrobial activity, and focused their purification efforts on
the antimicrobially active fractions. They identified a novel AMP, using peptide
sequence analysis with the hinge region is highlighted in red:
H-GWGSFFKKAAHVGKHVGKAALTHYL-OH.

They termed the novel AMP Pleurocidin.

After they isolated and determined the molecular weight of the isolated AMP using
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Matrix Assisted Laser Desorption Ionization Mass Spectrometry at 2711 [m+H]+, they
chemically synthesized it using the solid phase peptide synthesis (SPPS) method.
They determined the antimicrobial activity of synthetic Pleurocidin by reporting its
Minimum Inhibitory Concentration (MIC) against E.coli (6.0-9.0 μg/ml),
P.aeruginosa (>94.9 μg/ml), B.subtilus (3.0-6.0 μg/ml), and S.aureus (48.0-94.9
μg/ml) (Cole et al, 1996).
Jia et al described the design scheme pioneered by Merrifield et al to produce novel
antimicrobial peptides for use against bacterial fish pathogens. This hybrid method of
creating novel AMPs used entire sequences of one type of peptide paired with selected
stretches of other sequences. The first four peptides listed in Table 2 were all natural
AMPs that were isolated from 4 different species: Ceratoxin was derived from
Drosophila melanogaster, Dermaseptin was a skin secretion found in Phylomedusa
sauvagii, Misgurin was isolated from Misgurnus anguillicaudatus, and Pleurocidin
was found in the mucal skin secretions of Pseudopleuronectus americanus. The
remaining eight AMP sequences were the novel AMP designs. Pleurocidin amide was
created by adding an amide group to the C-terminal end. P-1 and P-1 amide were
peptides that had essentially the same sequence as Pleurocidin and Pleurocidin amide;
the only modification was one additional lysine added onto the N-terminus. This
alteration increased the net cationic charge, and made the N-terminus more polar. The
design of the remaining set of novel AMPs involved a hybrid approach, swapping out
entire sections of different natural AMPs to create combined properties that could
potentially lead to greater antimicrobial activity. The first hybrid of this type listed
was called P-DER, which used the first 9 residues of the N-terminal end of
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Dermaseptin and the last 17 residues of the C-terminal end of Pleurocidin. The
remaining hybrids also used combinations of Pleurocidin paired with Misgurin and
Ceratoxin (Jia et al, 2000).
Table 2: Extant and Novel Antimicrobial Peptide Sequences. This table shows one
design strategy for making hybrid AMPs (Jia et al). All sequences are aligned, and
color coded to indicate which segments from the natural AMPs were incorporated into
the Novel Peptide Hybrids. The first four sequences were derived from nature.
Pleurocidin-amide had a C-terminal amide designed to decrease hemolysis; P1 and P1amide had an N-terminal lysine to increase cationic charge. All the remaining novel
sequences were hybrids: P-DER combined portions of Dermaseptin and Pleurocidin;
P-CER used Ceratoxin and Pleurocidin; P-M used Pleurocidin and Misgurin; DER-M
used Dermaseptin, Pleurocidin and Misgurin; CER-M: used Ceratoxin, Pleurocidin
and Misgurin.
Categories

Names

Sequences

Natural AMPs

Ceratoxin:
Dermaseptin:
Misgurin:
Pleurocidin:
Pleurocidin amide:
P1:
P1 amide:
P-DER:
P-CER:
P-M:
DER-M:
CER-M:

1
5
10
15
20
25
H-SIGSAFKKALPVAKKIGKAALPIAKAALP-OH
H-ALWKTMLKKLGTMALHAGKAALGAAADTISQTQ-OH
H-RQRVEELSKFSKKGAAARRRK-OH
H-GWGSFFKKAAHVGKHVGKAALTHYL-OH
H-GWGSFFKKAAHVGKHVGKAALTHYL-NH2
H-KGWGSFFKKAAHVGKHVGKAALTHYL-OH
H-KGWGSFFKKAAHVGKHVGKAALTHYL-NH2
H-ALWKTMLKKAAHVGKHVGKAALTHYL-NH2
H-SIGSAFKKAAHVGKHVGKAALTHYL-NH2
H-GWGSFFKKAAHVGKHVGKAALGAAARRRK-OH
H-ALWKTMLKKAAHVGKHVGKAALGAAARRRK-OH
H-SIGSAFKKAAHVGKHVGKAALGAAARRRK-OH

Novel Peptide
Hybrids

Table 3 shows the antimicrobial activity of the various AMPs against various
pathogenic strains of bacteria that infect fish, as well as Pseudomonas aeruginosa and
Staphylococcus epidermidis. The MICs were determined in a 96-well plate using a
broth microtiter assay that demonstrated 50% inhibition of bacterial growth as
compared to a control using no AMPs (Jia et al, 2000). The C-terminal amide on
Pleurocidin amide increased the activity by as much as sixteen-fold over native
Pleurocidin. The antimicrobial activity of P1/P1 amide only increased against the
representative bacterial species up to a two-fold amount. P-DER had the greatest
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overall activity of all the hybrid sequences, although it was slightly less active than
Pleurocidin-amide. The remaining AMP hybrids were much less active than P-DER
(Jia et al, 2000).
Table 3: AMP Activity against Fish and Human Pathogenic Bacteria. The
peptides made by Jia et al were assayed against representative species of gram positive
and gram negative species. The Minimum Inhibitory Concentration (MIC) was
expressed as the lowest concentration of AMPs that inhibited overnight bacterial
growth by 50%. Results were as follows: Misgurin and CER-M were inactive,
Pleurocidin, P1, P-CER, P-M, and DER-M were only active against specific species;
Pleurocidin amide, P1 amide and P-DER were broad spectrum active in potency.

Peptide

V.
anguillarum

Misgurin:
Pleurocidin:
Pleurocidin
amide:
P1:
P1 amide:
P-DER:
P-CER:
P-M:
DER-M:
CER-M:

A.
salmonicida

MIC (ug/ml)
S.
enterica

S.
enterica

>64
16
2

>64
2
1

Serovar
Typhimurium
Strain:
14028s
>64
32
4

16
2
4
64
32
>64
>64

2
1
1
8
1
2
32

16
2
4
>64
16
32
>64

Serovar
Typhimurium
Strain:
14028s
>64
<0.5
<0.5
<0.5
<0.5
0.5
2
0.5
0.5
8

P.
aeruginosa

P.
aeruginosa

S.
epidermidis

Strain:
K799

Strain:
Z61

Strain:
C621

>64
64
4

>64
16
4

>64
64
4

64
2
4
>64
16
32
>64

8
2
8
>64
16
8
64

64
2
4
>64
16
32
>64

2.2.2 Optimizing Hybrid Cationic Alpha Helical Antimicrobial Peptides
As seen in Table 4, Strandberg et al noted that the natural sequence PGLa from
Xenopus laevis was potent; they modified the sequence and generated the novel
sequence MSI-103 by simplifying the types of different residues from eight to four.
The third AMP was a synthetic, hemolytic peptide called MAP that only had three
different types of residues. An active AMP with fewer types of residues simplifies
synthesis time and expense. Both the C-terminal free acid (-OH), and amidated
(-NH2) versions of all three peptides were synthesized, purified, and tested for activity
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against human pathogens. They discovered a free C-terminal acid residue raised the
Minimum Inhibitory Concentrations of four test peptides when compared to identical
sequences with C-terminal amidation. This sequence alteration decreased their
effectiveness, in some cases by as much as a factor of sixteenfold. In no instance, did
adding a C-terminal amide group lower the activity of an AMP. The synthetic
sequence MSI-103, with simplified residues as compared to the natural sequence
PGLa, was only marginally more effective in amidated form, but exhibited much
improved activity in free acid form. At the same time, the additional C-terminal
amide group increased the hemolytic potential of the peptides, and then only at a
therapeutically-useless high concentration for the MAP sequence, which was
hemolytic to start with (Strandberg et al, 2007).
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Table 4: AMP Activity and Human RBC Hemolysis. The peptides made by
Strandberg et al were assayed against representative species of gram positive and
gram negative species, and the MICs were determined. They were also assayed
against Human erythrocytes and the amount required causing 50% hemolysis after 1
hour was determined. PGLa-NH2, the first AMP sequence was from nature. PGLaOH had exactly the same sequence, but its C-terminus was a free acid. The remaining
AMPs were synthetic in design as part of an effort to determine properties that made
effective AMPs. MSI-103 used only 4 residue types, but it was nonhemolytic; MAP
used only 3 residue types, and it was extremely hemolytic. PGLa-OH and MAP-OH
were inactive against the bacterial species; MSI-103-OH and MAP-NH2 were only
active against specific species; PGLaNH2, and MSI-103-NH2 were broad spectrum
active. Both of the MAP peptides were hemolytic, so only the PGLaNH2, and MSI103-NH2 sequences were useful at therapeutic doses.
MIC (ug/ml)
E.coli
strain:
DSM
1103

HC50 (ug/ml)

E.coli
strain:
DH
5α

B.subtilus
strain:
ATCC
6633

S.aureus
strain:
DSM
1104

Human
RBCs

PGLa-NH2:

16

8

4

16

800

PGLa-OH:

>128

>128

32

>128

>1000

MSI-103-NH2:

8

16

4

8

1000

MSI-103-OH:

8

16

8

128

>1000

MAP-NH2:

128

8

4

32

7

MAP-OH:

>128

>128

>128

>128

11

H-GMASKAGAIAGKIAKVALKAL-NH2

Peptide

H-GMASKAGAIAGKIAKVALKAL-OH
H-KIAGKIAKIAGKIAKIAGKIA-NH2
H-KIAGKIAKIAGKIAKIAGKIA-OH
H-KLALKLALKALKAALKLA-NH2
H-KLALKLALKALKAALKLA-OH

Jiang of the Hodges research group experimented with the composition of the
hydrophobic faces of alpha-helical, amphipathic peptides; they noted that certain gram
negative bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii have
evolved many strains that are resistant to multiple classes of antibiotics. Active
anitimicrobial peptides could be designed to inhibit bacterial growth, even of the
multidrug resistant strains. However, one of the major hurdles of making novel AMPs
was the issue of potential hemolysis of human red blood cells; an active AMP that is
too hemolytic is not therapeutically useful. A sequence was selected that was
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antimicrobially active against strains isolated from living organisms, but was too
hemolytic. The research group then made systematic residue changes in an attempt to
reduce the hemolytic properties of the peptides without compromising antimicrobial
activity. The initial change was the insertion of a positively charged lysine into the
center of the hydrophobic face of the α-helix, in a key position they termed the
“Specificity Determinant”. More positive charges were added by switching additional
neutral residues into lysines; this increased the overall hydrophillicity and positive
charge of the polar face of the helix. They then converted selected side chains of
amino acid residues from aromatic into aliaphatic; having perfectly hydrophobic faces
encouraged peptide aggregation and also increased AMP hemolytic activity. Inserting
a disruptive, positively charged, polar residue in the “Specificity Determinant” of the
hydrophobic face of the helix, curtailed dimer formation, and reduced the effects of
hemolysis (Jiang et al, 2011).
2.3 Hybrid Cationic Alpha Helical Antimicrobial Peptides In Silico Design
Strategies
In silico design is useful to aid in peptide design as these tools can evaluate a series
of AMPs to determine their potential utility without going through the time and
expense to synthesize the prospective sequences.
2.3.1 Chou-Fasman Secondary Structure Algorithm
The first in silico tool is the Chou-Fasman secondary structure algorithm; it
predicts potential secondary structures based on their amino acid sequences. Using
this algorithm, there are three types of secondary structures that are modeled: coiled
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alpha helices, ribbon-shaped beta sheets, and 4-residue beta turns. The algorithm
assigns a prediction of what secondary structure a given stretch of the protein will
form based on residue affinity and composition (Chou and Fasman, 1978). Figure 5
shows a printout of P-DER as modeled by the Peptide Companion® Chou-Fasman
algorithm (Lebl, 1994).

Figure 5: Chou-Fasman Secondary Structural Model of P-DER. The three line
graphs show the three common secondary structures: alpha helixes (green), beta sheets
(red), and beta turns (blue). The likelihood of formation of the secondary structure
configuration is plotted against the AMP sequence from the N-terminus to the Cterminus. In this example, P-DER has two strong alpha helical sequences at the
N-terminal and C-terminal ends, separated by an unstructured domain.
2.3.2 Edmundson Helical Wheel
The second in silico tool is the Edmunson helical wheel; it portrays a side view of a
potential alpha helix, showing how amphipathic the faces of the helix are (Schiffer and
Edmundson, 1967). The model displays an end-on, 2D view of the helix as viewed
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from the N-terminus. There are 4 different residue types: hydrophobic, neutral polar,
acidic and basic. How they are arranged in the model determines how amphipathic the
alpha helical AMP is. Figure 6 shows a printout of P-DER as modeled by the Peptide
Companion® Edmundson helical wheel (Lebl, 1994).

Figure 6: Edmundson helical wheel of P-DER. The top diagram models an
N-terminal end-on view of an alpha helix. Residues are assigned to 4 different
categories: hydrophobic side chains (green), hydrophilic side chains (maroon), acidic
side chains (red) and basic side chains (blue). P-DER was strongly amphipathic, with
well developed hydrophilic and hydrophobic faces. The bottom diagram models a
helical net, which is a side view of an unrolled α-helix.
2.3.3 Hopp-Woods Hydrophilicity Scale
The third in silico tool is the Hoop-Woods hydrophilicity scale to model the
proposed hybrids in order to evaluate what stretches of a peptide sequence were likely
to be hydrophilic or hydrophobic (Hopp and Woods, 1981). All sequences that
displayed extreme transitions between hydrophilic and hydrophobic characteristics at
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their junctions were judged as being too unpredictable to mimic the natural
conformations adopted by natural AMPs, and were rejected. Figure 7 shows a printout
of P-DER as modeled by the Peptide Companion® Hopp-Woods hydrophilicity scale
(Lebl, 1994).

Figure 7: Hopp-Woods Hydrophilicity Scale of P-DER. Hydrophobic to
hydrophilic character was plotted against the AMP sequence from the N-terminus to
the C-terminus. In this case, the P-DER AMP had a strongly hydrophilic N-terminal
region, followed by a more hydrophobic C-terminal region.
Summary
The overall strategy used to design the AMPs in this project was to note the
biophysical and antimicrobial properties of known and hybrid AMP sequences before
the resources were invested on producing them. Due to P-DER being the most potent
hybrid AMP from the Jia et al experiments, it was used as the starting point for all the
novel AMP sequences in this project (Jia et al, 2000). P-DER became the initial test
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case into how AMP hybrids might be designed to further improve their therapeutic
properties. The novel hybrid P-DER derivatives LM7-1 and LM7-2 featured novel
C-terminal amidation designed to increase antibacterial activity, without significantly
increasing hemolytic potential at potentially therapeutic doses. As a consequence,
MBHA resin was used for all of the peptide synthesis, so that when the peptide chains
were cleaved off, the AMP would possess a C-terminal amide group (Strandberg et al,
2007). All of the designed peptides in this project used a “Specificity Determinant”.
This design strategy is designed so that the nonpolar faces do not easily aggregate to
form multimers; such hybrids should exhibit decreased hemolysis. Cationic,
alpha-helical AMPs are more effective in penetrating bacterial cell walls when they
operate individually as opposed to acting in massed aggregates (Jiang et al, 2011).
LM7-1 and LM7-2 were designed to be conformationally flexible AMPs, having
unstructured secondary structures in an aqueous environment. These AMPs should
only form amphipathic alpha-helices when they are in direct contact with a cell
membrane. AMP sequences that avoided forming a stable alpha helix when free in
solution, and formed a well defined secondary structure when in contact with a
membrane surface were used to lower the possibility of unintentional hemolysis
(Toke, 2005). Both AMPs also featured an α-helix-hinge-α-helix structural motif; this
was an important innovation taken from the design of CEME (Boman et al, 1989).
When depicted in the Edmundson helical wheel format, it was clear that both peptides
had smaller hydrophilic faces compared to their hydrophobic faces; this arrangement
contributed to a membrane destabilizing role that would be consistent with the
“carpet” model of AMP action on bacterial cell membranes (Toke, 2005). Both LM7-
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1 and LM7-2 were hybrid peptides, having N-terminal and C-terminal sequences
drawn from two different natural AMPs. LM7-1 also incorporated a one-residue
substitution at position 15 to increase hinge flexibility. These AMP characteristics
were also used to design three additional novel hybrids. The design started with the
potent hybrid, CEME and combined it with three natural AMPs to create LM7-3,
LM7-4 and LM7-5.
The hypothesis for this Thesis Project is that novel, therapeutically useful, hybrid
AMP analogues can be generated by linking carefully chosen sequences from one
peptide with a region from a different peptide. This goal can be achieved through
careful analysis of the helix-forming propensity and amphipathicity of each sequence,
and placement of a hinge between the segments such that the activity is not diminished
(Andreu, 1992). This hybrid approach should allow the production of many new
AMPs that have the efficacy of natural sequences but may circumvent resistance
mechanisms that arise in the target bacteria, due to their cationic charges drawing
them towards negatively charged bacterial cell wall and cell membrane components.
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CHAPTER 3
MATERIALS AND METHODS
3.1 Equipment and Reagents
3.1.1 Equipment
The manual peptide synthesis reaction vessels were purchased from Peptides
International (KY, USA). The manual peptide shakers were from St.John’s Associates
(MD, USA). The heating blocks were from VWR (PA, USA). Borosilicate glass
pipettes, 0.5 x 6.0 cm tubes, and magnetic stir bars were from Thermo Fisher
Scientific (NH, USA). The HF apparatus, and Kel-F® tubes were from Immuno
Dynamics (CA, USA). The 2.5 x 112.0 cm Glass Chromatography column and
tubing was from Sigma-Aldrich (MO, USA). The Rabbit Plus peristaltic pump, and
automatic pipettes were from Ranin (OH, USA). The in-line UV/VIS detector was
from Kratos Analytical (Spectraflow 783, Kyoto, Japan). The fraction collector was
manufactured by Gilson (FC 205, WI, USA). The Chart Recorder was made by
Linear (Tamil Nadu, India). The RE rotary evaporator and accessories were made by
Büchi (Postfarch, Switzerland). The automatic 7010 injector valve was manufactured
by Rheodyne (CA, USA). The preparatory reversed Phase HPLC column was from
Vydac (300 Å, 10 μ, C18, 2.2 x 25.0 cm, 218 TP 152022, IL, USA). The HPLC
minipump was from Thermo Separation Products (OR262520, NH, USA). The
lyophilizer was from Virtis (PA, USA); the lyophilizing dewars were from Labconco
(IL, USA). The MALDI-MS was from Ciphergen (ProtienChip™, CA, USA), and the
ESI-MS was from Thermo Fisher Scientific (LTQ Orbitrap Velos, NH, USA). The
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Genesys 10UV Scanning Spectrophotometer was from Thermo Scientific (6 carousel,
UV-VIS, 190-1100 nm range, NH, USA). The Spectronic 20D was from Milton Roy
(PA, USA). The Vmax Kinetic Microplate reader was from Molecular Devices
(405/450/570/630 nm, CA, USA). The IEC clinical centrifuge was from International
Equipment Corporation (MA, USA). The G10 Gyrotary shaker was from New
Brunswick Scientific (NJ, USA). The Petri dishes were from Kard-Valmark (Plastic,
100 x 10 mm, #2900, Ontario, Canada). The -80°C freezer, autoclave, crushed ice
machine, cold room, purified (pyrogen-free) water system, high pressure air lines, high
pressure vacuum lines were provided by the Cell and Molecular Biology Department
at the University of Rhode Island.
3.1.2 Chemical Reagents
All of the solvents except trifluoroacetic acid were HPLC grade; TFA was
Technical grade. All of the solid reagents except potassium hydroxide were American
Chemical Society standard, KOH was technical grade. The amino acids used were as
follows (side chain protecting groups are indicated in brackets): Boc-L-Ala-OH,
Boc-L-Arg(Tos)-OH, Boc-L-Asn-OH, Boc-Gly-OH, Boc-L-His(DNP)-OH,
Boc-L-Leu-OH, Boc-L-Met-OH, Boc-L-Pro-OH, Boc-L-Ser(Bzl)-OH,
Boc-L-Tyr(Bzl)-OH, Boc-L-Thr(Bzl)-OH, and Boc-L-Trp-OH were all purchased
from Bachem. In addition, Boc-L-Ile-OH, Boc-L-Lys(2-Chloro-CBZ)-OH, and
Boc-Phe-OH were purchased from Peptides International (KY, USA); Boc-L-Val-OH
was purchased from The Peptide Institute (Saito, Japan). The
p-methylbenzhydrylamine Resin●HCl used for SPPS was from Peptides International

27

(RMB-1045-PL,100-200 mesh, 0.40 miliequivalents/g, KY, USA). Calcium
gluconate gel was from Attard Minerals (CA, USA). Dichloromethane, N,Ndiisopropylamine, N,N-dimethylformaide, trifluoroacetic acid,
N,N’-dicyclohexylcarbodiimide, 1-hydroxybenzotriazole, 2-(1H-benzotriazole-1-yl)1,1,3,3-tetramethyluronium hexafluorophosphate, methanol, 95% isopropanol,
potassium chloride, phenol, magnesium sulfate, potassium hydroxide, thiophenol,
glacial acetic acid, blue dextran, acetonitrile, p-cresol, p-thiocresol, formic acid,
chloramphenicol, solid potassium hydroxide, Triton® X-100, sodium chloride, sodium
phosphate monobasic, sodium phosphate dibasic, MB-3 Amberlite®, G25 Sephedex®,
sinapic acid, Mueller Hinton broth, Mueller Hinton agar, Nutrient agar, and Parafilm®
were all from Fischer Sigma-Aldrich (MO, USA) or Wilkem (RI, USA). 95% ethanol
and absolute ethanol were supplied by the University of RI. Hydrofluoric acid, argon,
and nitrogen gasses were supplied by Airgas (RI, USA). Dry ice was supplied by
Corp Brothers Inc. (RI, USA).
3.2 Solid Phase Peptide Synthesis (SPPS)
3.2.1 Modes of Solid Phase Peptide Synthesis
SPPS is directly reversed from the direction of enzymatic peptide synthesis; instead
of travelling from the N-terminus to the C-terminus, SPPS elongates the peptide chains
in the opposite direction. There are two orthogonal modes of SPPS, based on the
choice of protection for the N-terminus of the amino acid building blocks. One
scheme uses an acid-cleaved tert-butyloxycarbonyl (Boc) protecting group and the
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other uses a base-cleaved 9-fluorenylmethyloxycarbonyl (Fmoc) protecting group. The
Boc method was used for all the peptide synthesis for this Thesis.
SPPS grows the peptide chain out from solid resin support beads. The beads are an
essential element to SPPS, because the reaction vessel used for the synthesis has a
fritted filter on the bottom that prevents the peptide-bound resin from falling out,
while liquid reagents are added and suctioned out freely. The type of support resin
chosen depends on what type of C-terminal functional group is desired; naturallyoccurring peptides may contain a free C-terminal acid group or a C-terminal amide
group. In this case, synthesized peptides were made with a C-terminal amide by using
4-methylbenzhydrylamine (MBHA) resin. After the resin is prepared, amino acids
are added sequentially to the growing peptide chain in a C-terminal to N-terminal
order. Every amino acid has a Boc protecting group blocking the reactive amino
group so that only its C-terminus couples with the reactive amino groups on the
growing chains. Any reactive side chains of the amino acids are also blocked using
labile protecting groups until the peptide elongation is finished. After each coupling
cycle has been pushed to completion, the new N-terminal Boc group is cleaved off
using 50% trifluoroacetic acid (TFA) in dichloromethane (DCM) for 30 minutes, and
the coupling cycle is repeated until the peptide is complete. Later, most of the side
chains are deprotected at the same time as the anchoring C-terminus of the peptide is
cleaved from the resin, using anhydrous hydrofluoric acid (HF) at 0°C for 1 hr.
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3.2.2 Peptide Synthesis Procedure with Ninhydrin Monitoring
LM7-1 through LM7-5 were synthesized using the Boc method of SPPS. A sample
of 2 g of MBHA Resin HL (100-200 mesh)●HCl, with a reported substitution of 0.40
milimoles/g were swollen in dichloromethane (DCM) overnight, and the ninhydrin test
was used to quantify the amount of free amino groups on the Resin beads. This
determined how many peptide chains could grow on the surface of the beads and
dictated how much of any incoming amino acid would be needed to perform a
complete coupling reaction.
The quanitative ninhydrin test (Kaiser test) proceeded as follows: 1-2 mg of sample
resin was combined with the ninhydrin reagents in a tube, and then incubated in a
block heater which was set to 100ºC for exactly 10 minutes. A second tube without
resin was also set up as a control. In the presence of free amine groups, a blue, light
absorbing complex formed; otherwise the solution remained yellow if amines were
present at a concentration of <0.01% (Sarin et al, 1981). To exactly quantify the free
amino groups, the test sample was then filtered to remove the resin. The eluent was
diluted to exactly a 10.0 ml total volume with absolute ethanol, and mixed. An aliquot
was then scanned at 570 nm to detect the absorption of the Ruhemann’s purple
pigment. The absorbance was used to calculate the concentration of amine groups in
that particular volume according to the published Ruhemann’s extinction coefficient,
which was 1.55 x 103 L cm-1 mol-1 (Sarin et al, 1981). This specific “loading” value
was used to determine the quantity of Boc-amino acid which was needed for a given
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coupling reaction. The loading equation to determine mmoles anino groups/g resin is
listed below:

A  lc

(1)



A570   570 L

cmmol 
L

mol  cm

 l

cm

 cmol

L

A570  1000 mmol 


 570l   1mol 

Resin Loading = cmmol  cmmol 
g

L

Vtot , L
 1000 mg 

 
mg resin sample 
g


(2)

(3)

(4)

Loading (in mmol/g) x resin mass (in g) used in synthesis =“1 Equivalent” (5)
In all cases, an excess of the Boc amino acids were used to drive the coupling
reactions to completion, typically >99.99%. If the ninhydrin test was negative
(colorless) after coupling, the synthesis proceeded on to the next residue in the
sequence. If it was still positive (blue), then different coupling protocols were used
until the incoming Boc amino acid had successfully coupled with all of the available
amine groups on the resin beads, resulting in a negative Kaiser test.
The coupling steps were carried out using one of four different coupling protocols
as needed, starting with the direct DCC coupling protocol shown in Figure 8. In this
coupling method, the carboxylic acid functionality of a N-Boc-L-amino acid is
activated by coupling to N, N’-dicyclohexylcarbodiimide, and then the N-Boc-Lamino acid containing the more reactive O-acyl-isourea leaving group directly
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couples with the free amino group on the growing peptide chain. When the activated
Boc-AA is mixed with the peptide resin, the exposed lone pair of electrons on the
amino group at the N-terminus of the peptide chain attack at the partially positively
charged carbonyl carbon on the amino acid, forming a tetrahedral intermediate,
followed by elimination of the O-acyl-isourea leaving group, with formation of a
stable peptide bond. After coupling, the result is the peptide is increased in length by
one amino acid. More expensive and reactive coupling reagents were used whenever
a positive ninhydrin test showed that the direct DCC coupling protocol did not result
in total coupling of the incoming activated Boc-AAs with all of the target growing
peptide chains on the resin (<0.01% unreacted amino groups).
To use the protocol, 50% TFA in DCM was used to cleave off the Boc protecting
groups, and the peptide resin was washed and neutralized with 20% DIEA in DCM.
Then 5 equivalents of Boc-AA were dissolved in a minimal amount of DMF in a clean
Erlenmeyer flask and added to the reaction vessel. Afterwards, 5 equivalents of a
calibrated solution of exactly 0.5 M DCC in DCM was added to the RV and the direct
coupling reaction was run for 90 minutes.
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Figure 8: Direct DCC Catalyzed Coupling Protocol. The N-Boc-L-amino acid is
activated by coupling to N, N’-dicyclohexylcarbodiimide, forming the O-acyl-isourea
leaving group and directly reacts with the free amino group on the peptide-resin. The
result is an extended peptide chain.

In the Symmetric Anhydride coupling protocol, as shown in Figure 9, the N-Boc-Lamino acid is activated by coupling to N, N’-dicyclohexylcarbodiimide, and then an
excess of the identical N-Boc-L-amino acid replaces the O-acyl-isourea functional
group. The pre-formed symmetric anhydride is extremely reactive and couples with
any free amine groups remaining on the peptide-resin. The exposed lone pair
electrons on the amine group at the N-terminus of the peptide chain attacks the
carbonyl group on the symmetric anhydride, removing one of the N-Boc-L-amino
acids as a leaving group, and forming a peptide bond with the other one. After
coupling, the peptide is increased in length by one amino acid.
To use the Pre-formed, Symmetric Anhydride protocol, the peptide resin was
washed with DCM, neutralized with 10% DIEA in DCM, and then drained. Then, 2
equivalents of incoming Boc-AA were dissolved in a minimal amount of DMF in a
clean Erlenmeyer flask, and this solution was added to the resin in the reaction vessel.
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Afterwards, 1 equivalent of a calibrated solution of exactly 0.5 M DCC in DCM was
added to the RV and the Symmetric Anhydride coupling reaction was run for 60
minutes.

Figure 9: Pre-formed Symmetric Anhydride Protocol. The N-Boc-L-amino acid is
activated by coupling to N, N’-dicyclohexylcarbodiimide, and then the same N-Boc-Lamino acid replaces the O-acyl-isourea group. The pre-formed symmetric anhydride
reacts with the free amino groups, and produces a peptide bond with one of the
remaining N-Boc-L-amino acid residues as a leaving group. The result is an extended
peptide chain.

In the Direct HOBt coupling protocol, as shown in Figure 10, the N-Boc-L-amino
acid is pre-activated by coupling to N,N’-dicyclohexylcarbodiimide, and then Nhydroxybenzotriazole (HOBt) replaces the O-acyl-isourea functional group. The
HOBt Active ester serves to prevent the amino acid from reversing its chirality during
coupling. When the HOBt active ester is mixed with the peptide resin, the exposed
lone pair of electrons on the amino group at the N-terminus of the peptide chain
attacks the carbonyl group on the Boc-amino acid, removing the HOBt as a leaving
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group, and forming a peptide bond. After coupling, the peptide is increased in length
by one amino acid.
To use the HOBt coupling protocol the peptide resin was washed with DCM,
neutralized with 10% DIEA in DCM, and drained. Then, 4 equivalents of Boc-AA
and 4 equivalents of HOBt were dissolved using a minimal amount of DMF in a clean
Erlenmeyer flask. After the solution was added to the reaction vessel, 4 equivalents of
DCC was added to the RV and the coupling reaction was run for 90 minutes.

Figure 10: Direct HOBt Coupling Protocol. The N-Boc-L-amino acid is preactivated by coupling to N,N’-dicyclohexylcarbodiimide, and then
1-hydroxybenzotriazole (HOBt) replaces the O-acyl-isourea functional group. The
exposed amino group reacts with the HOBt active ester to produce a novel peptide
bond, and the HOBt leaving group is removed. The result is an extended peptide
chain.

In the HBTU coupling method, as shown in Figure 11, the N-Boc-L-amino acid is
pre-activated by coupling to 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyuronium
hexafluoride phosphate (HBTU). The ionized acid group of the N-Boc-L-amino acid
attacks the tetramethyl group and forms a tetramethyluronium active ester. The newly
formed N-Hydroxybenzotriazole (HOBt) attacks the carbonyl in the ester group, and
1,1,3,3-tetramethylurea acts as a leaving group. When the HOBt active ester is mixed
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with the peptide resin, the exposed lone pair electrons on the amine group at the Nterminus of the peptide chain attacks the carbonyl group on the Boc-amino acid,
removing the HOBt as a leaving group, and forming a peptide bond. After coupling,
the peptide is increased in length by one amino acid.
To use the HBTU protocol the peptide resin was washed with DCM, neutralized
with 10% DIEA, and drained. Then 5 equivalents of Boc-AA and 5 equivalents of
HBTU were dissolved using a minimal amount of DMF in a clean Erlenmyer flask, 10
equivalents of 20% DIEA in DCM was added to the flask, and the mixed flask
contents were added to the reaction vessel. The coupling reaction was run for 90
minutes.

Figure 11: Direct HBTU Coupling Protocol. In this coupling method, the N-Boc-Lamino acid is pre-activated by coupling to 2-(1H-benzotriazole-1-yl)-1,1,3,3tetramethyuronium hexafluoride phosphate (HBTU). The tetramethyluronium leaving
group on the active ester is replaced by HOBt. The exposed amino group reacts with
the HOBt active ester to produce a novel peptide bond, and the HOBt leaving group is
removed. The result is an extended peptide chain.
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3.2.3 Histidine-dinitrophenol Removal Protocol
All of the protecting groups attached to the side chains of the Boc amino acids used
in the SPPS were labile to hydrofluoric acid cleavage; the lone exception was the
dinitrophenol (DNP) protecting group on the side chain of histidine. DNP removal
needed to precede HF cleavage; otherwise, the freed DNP molecules might react
elsewhere on the peptide. As both LM7-1 and LM7-2 contained Histidines, the DNP
groups were removed by using 20 mmol of noxious thiophenol in 5 ml DMF for each
mmol of His (DNP) present in the product peptide (0.102 ml/mmol, or 2 ml
thiophenol/mmol). The mixture was gently agitated for 1-4 hrs at room temperature,
drained, and the peptide-resin was washed with solvents multiple times until the
thiophenol and its associated foul odors were removed.
3.2.4 Anhydrous High Hydrofluoric Acid Cleavage Protocol
The N-terminal Boc group was removed using TFA: DCM (1:1, 2 + 30 min); this
was done before the HF cleavage so that the Boc byproducts would not alkylate any
deprotected regions of the peptide. The “DNP-free”, Boc-deprotected peptide-resin
was washed with DCM several times and then dried using reduced pressure from a
water aspirator.
The peptide-sample was then divided into 2x 1.0 g peptide-resin aliquots and placed
them into two separate Kel-F™ HF cleavage vessels, along with a teflon-coated stir
bar. The vial lids were added, the lids were covered with Parafilm®, vent holes were
poked in the Parafilm®, and the samples were completely dried under high vacuum
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with the lyophilizer overnight. Afterwards, a scavanger mixture of 1 ml of p-cresol
and 1 ml of p-thiocresol was added to each vial containing the dry peptide-resin (1%
v/w).
The HF apparatus was leak-checked with N2 gas after mounting the peptide-resin
(RV) reaction vessels, to ensure the system was closed. The apparatus outlet passed
through a 8M aqueous KOH trap to neutralize any excess HF. The HF vials were
cooled to -78ºC in vacuum dewer flasks containing a slurry of isopropanol and dry ice
for 20 minutes, before 10 ml of room temperature HF was distilled into each chilled
vial. Once the correct volume of HF was added, the vials were stirred and allowed to
warm up to 0°C with an ice-water mixture for 1 hour; the HF cleaved off the peptides
from the support resin, and it also removed the remaining side chain protecting groups.
When the HF reaction was complete, the vials were allowed to warm up to room
temperature, and N2 gas was used to blow off any remaining HF into the KOH trap,
and to dry out the product crude peptides and resin. Suction from a water aspirator
was used to completely dry out the resin vessels and apparatus, and then the HF
vessels containing resin, scavengers, and crude product peptides were unscrewed from
the apparatus.
The organic scavengers from the peptide-resin were extracted with diethyl ether
twice, and then the crude peptide was extracted from the solid resin using 10% (v/v)
aqueous acetic acid, and any insoluble peptide remnants were further extracted using
glacial acetic acid. The 10% and glacial acetic acid extracts with the crude peptide
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were lyophilized and the yield of crude peptide was determined. The remaining solid
from the extractions was the polystyrene-divinylbenzene support resin.
3.3 Liquid Chromatography Purification
3.3.1 Gel Filtration Liquid Chromatography with a G25 Sephedex® Column
The glass Liquid Chromatography column was fitted with a fritted outlet filter.
The column was filled with pre-swollen G25 Sephedex® in 10% (v/v) aqueous acetic
acid to form a packed gel filtration bed of 2.5 x 86 cm. Above the column, 10% (v/v)
aqueous acetic acid was added via a peristaltic pump from a reservoir. Below the
column outlet, the drain line was routed through a preparative flow cell in a UV
absorbance detector, which was set to 280 nm to quantify relative amounts of
tryptophan present as the peaks eluted. The detector output was recorded on a chart
recorder such that the analog chromatogram was annotated with absorbance data
readings noted during the run. The eluent was deposited into fraction tubes so that the
peptide product peak was collected separately from the synthesis waste. Once the
column bed was set up and leak tested, a blue dextran solution was run through the
column to determine the column void volume (~160 ml); the dye ran though the
column without being retained by the Sephedex® beads.
The crude peptide was then dissolved in 10% (v/v) aqueous acetic acid so the
concentration was roughly 25 mg/ml. The liquid in the column was then drained
down to just over the top of the Sephedex® bed; a 3 ml sample was layered across the
top of the stationary phase bed yielding 75 mg of crude peptide. The sample was
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drained into the top of the Sephedex bed, and a head space of 10% acetic acid was
added. The peristaltic pump was started, and the eluent was routed through the UV
detector.
As shown in Figure 12, the first column “void” volume (~160 ml) was always
discarded. The second column volume, which contained the purified peptide, was
collected in

13 x 100 mm fraction tubes in 3 ml/tube (160 ml/3 column volumes =

53.3 ml/column volume). The third column volume, with impure peptides and
scavengers, was collected separately. The fraction tubes were processed by scanning
them individually in a spectrophotometer at 280 nm to determine the true absorbance
values where the sample was the most concentrated. The point from where the first
peak started to elute to where the absorbance rapidly fell contained the purest peptide
product (Peak A); the point where the absorbance fell back down to baseline levels
contained impure products (Peak B). Peaks A and B were separately pooled and
frozen in a dry ice/isopropanol slurry and added to freeze dryer flasks. After the
samples were frozen, the flasks were connected to the lyophilizer; the acetic acid was
sublimed off, and the remaining dried, fluffy peptide sample was ready to be purified
further.
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Figure 12: Generic Gel Filtration Chromatography Plot. In this hypothetical
graph, absorbance at 280 nm is plotted against Fraction number. In a typical post-HF
cleavage peptide purification run, there are three major volumes produced. The first
column “void” volume represents the total liquid excluded from the stationary phase
and in the tubing. The second column volume represents the protein products not
retained by the gel filtration stationary phase. The third column volume represents
protein fragments, HF scavengers and salts retained by the gel filtration stationary
phase.

3.3.2 Reversed Phase Preparatory High Performance Liquid Chromatography
with a C18 Column
All the preparatory RP-HPLC runs were done with a 22 x 250 mm, Vydak 218TP,
C18 Reversed Phase column. The mobile phases were stored in bottles of varied
concentration ranging from 5% acetonitrile/95% water/0.1% TFA up to 95%
acetonitrile/5% water/0.1% TFA. From the reservoir bottle, the mobile phase was run
through a pump, and then through a six way Rheodyne 7010 injector valve up into the
column. The outlet line from the top of the column was routed through a flow cell
with a UV absorbance detector set to 220 nm to detect peptide bonds as the peaks of
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interest eluted. The eluent was deposited, 75 drops at a time (3 ml), into fraction tubes
so that similar products were later pooled. The UV detector was connected to a chart
recorder to provide a paper record of the RP-HPLC run.
The peptide mixtures were dissolved in 10% (v/v) aqueous acetic acid, ensuring
that the solution concentration was no higher than 10 mg/ml. The analyte solution was
refrigerated at 4ºC as a precaution to slow down any peptide degradation until it was
injected. Just prior to a RP-HPLC run, up to 5 ml of the peptide sample was loaded
into the sample loop in the Rheodyne® high pressure injection valve. Then 5%
acetonitrile/95% water/0.1% TFA was run through the column until the baseline
absorbance on the UV detector stabilized; the detector was then zeroed. The run was
started by switching the valve to inject the loaded peptide product inside the sample
loop into the column. For step gradient runs, the reservoir bottles were switched out
every time a higher concentration of acetonitrile was required, along with a
corresponding annotation written on the chromatogram. At the end of every run, 95%
acetonitrile/5% water/0.1% TFA was used to flush any remaining contaminants out of
the preparatory RP-HPLC column.
As shown in Figure 13, fraction tubes were processed into groups representing four
distinct zones: baseline absorbance outside of peaks, the leading edge & midpeak
regions, and the tail end of a peak. Baseline absorbance zones did not contain any
usable peptide, due to the low absorption indicating a lack of product. The leading
edge and midpeak regions had peptides of the highest purity, due to the fact that these
regions of a peak contain components of a very specific hydrophobicity that is
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partitioning out of the stationary phase into the mobile phase all at once. The tailing
edge frequently had impure products, because overlapping components are
partitioning into the mobile phase at a slower rate. Pooled fractions were placed on a
rotary evaporator and concentrated until all the acetonitrile was removed, and then the
aqueous samples were placed into 15 or 50 ml plastic centrifuge tubes. The pooled,
purified samples were frozen in using a dry ice/isopropanol slurry, pinholes were
made in the centrifuge tube caps, and the tubes were placed on the lyophilizer in
vacuum flasks until all the remaining solvents were sublimed away. The dried,
purified peptide samples were saved and frozen at -80°C.

Figure 13: Generic Reversed Phase High Performance Liquid Chromatography
Sample Peak. In this hypothetical graph, absorbance at 220 nm is plotted against
time in minutes. A single, generic protein peak is shown. The peak has background
absorbance before the peptide elutes, the leading edge & mid-peak regions contain the
purest product, and the peak tail is impure.
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3.4 Mass Spectroscopy
3.4.1 Matrix Assisted Laser Desorption Ionization-Time of Flight Mass
Spectrometry
Two ug/ml of a standard protein of known mass was used to calibrate the MALDITOF. Single crystals of dried peptides were dissolved in 35 μl of 10% (v/v) aqueous
acetic acid. Tenfold dilutions of the samples were made using a diluent mixture (50%
acetonitrile/49.95% water/0.05% trifluoroacetic acid). The sample plate was spotted
with 1 μl of 10 mg sinapic acid/ml diluent. Then 1 μl of the peptide sample was added
within the center of the matrix droplet, and the droplets were air dried. The plate was
placed in the MALDI-TOF sample holder and it was exposed to high vacuum
conditions. The MW standard was scanned first, and its value was used to correct any
deviations from its known mass. The rest of the samples were scanned with the laser
beam and the results were averaged and saved. The measured mass/charge (m/z)
values of individual HPLC fractions were used as a guide to pool the peptide samples
from multiple preparative RP-HPLC runs into appropriate fractions of the synthetic
peptide. Samples consisting of single peak with the desired mass were set aside and
frozen for use in antimicrobial testing.
3.4.2 Liquid Chromatography-Electrospray Ionization-Mass Spectrometry
(ESI-MS)
Single crystals of dried peptides in were dissolved in 20 μl of HPLC Buffer A
(50% acetonitrile/49.95% water/0.05% formic acid); 1 μl of the dissolved peptide
samples were injected into the HPLC column. A fraction of the chromatographic
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eluent was diverted into the mass spectrometer where a N2 sheath gas was added to the
flow to “spray” the eluting samples so that some droplets entered the ionization
chamber of the MS. The results in were recorded in terms of Retention Peaks, Total
Ion Chromatograms, and Selected Ion Chromatograms. The electrospray ionization
method results in multiply charged peptide. The Mass Spectrometer was then used to
determine m/z ratios of multiple peptide peaks having various charges (+1, +2, etc).
The m/z ratios were then deconvoluted using software that identifies patterns of peaks
which more than likely originated from a single original analyte peak of uncharged
mass.
3.5 Antimicrobial Assays
3.5.1 Antimicrobial 96-Well Plate Activity Assay
Mueller-Hinton media and agar was used for antimicrobial broth and plate assays,
Nutrient agar was used for maintaining bacterial stocks on slants. 1 loopful of each of
the 4 slant species (Esherichia coli, Enterococcus faecalis, Staphylococcus aureus,
and Pseudomonas aeruginosa) were transferred to separate 150 ml Erlenmyer flasks
containing broth media. The cultures were incubated overnight at 37°C, shaking at
200 RPM. The subcultures were set up by transferring one loopful of each overnight
broth culture into fresh, sterile broth media in 150 ml Erlenmyer flasks. The flasks
were incubated overnight again at 37°C, shaking at 200 RPM. Optical Density (OD)
was determined by using a Spec20 spectrophotometer set to 630 nm. An uninoculated
Mueller-Hinton broth sample was used to zero the absorbance, and then the samples
were read by placing 3 ml of the sample into a 13 x100 mm tube, vortexing it, and
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inserting the tube into the spectrophotometer. Each subculture was then diluted to a
starting OD630 of ~0.12.
The 96-well plate was typically set up as shown in Table 5. Each well had a
maximum capacity of 300 μl; the plate had 8 rows versus 12 columns. Test peptides
LM7-1/LM7-2 were suspended in a solution of filter-sterile Hancock Diluent (0.2%
Bovine Serum Albumin in 0.1% Acetic acid) to make an initial working concentration
of 5mg/ml, then 1:10 and 1:100 dilutions were also made. Chloramphenicol was used
at a working concentration of 0.1 mg/ml; this antibiotic was a control, used to calibrate
inhibition of bacterial growth. Using aseptic technique, sterile broth trays were filled
with 5 ml of the bacterial suspension at an OD630 of 0.12, and mixed with 10 ml of the
Muller-Hinton broth to make a “bacterial broth”. The wells in the 96-well plate were
then filled up. Each well in columns 2-6, 8-9, and 11 got 150 μl of the bacterial broth.
Then Mueller-Hinton media was added: 130 μl to all wells in column 3, 140 μl in all
wells in columns 4 + 8 + 9, 300 μl in all wells in columns 1 + 7 + 10. Then, 20 μl of
the neat initial AMP solution was added to all wells in Column 3, 10 ul to all wells in
column 4, 2 μl of the 1:10 AMP dilution was added to all wells in column 5, and 2 ul
of the 1:100 AMP dilution was added to all wells in column 6. Finally, 10 μl of 6M
NaOH was added to all wells in column 9, and 10 μl of chloramphenicol was added to
all wells in column 8.
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Table 5: Template for an Antibacterial Activity Assay. Results were monitored by
scanning 96-well plates at 630 nm. The contents were as follows: Media (MuellerHinton broth only), Bac (Esherichia coli, Enterococcus faecalis, Staphylococcus
aureus, or Pseudomonas aeruginosa), Dil (Dilution), AMP (LM7-1 or LM7-2),
Antibio (active antibiotic), 6 M NaOH (total cell kill solution). The columns are
different experimental conditions; the rows are replicates.
Media
only

Bac

A1
B1
C1
D1
E1
F1
G1
H1

A2
B2
C2
D2
E2
F2
G2
H2

Bac
AMP
Dil
A3
B3
C3
D3
E3
F3
G3
H3

Bac
AMP
Dil 2
A4
B4
C4
D4
E4
F4
G4
H4

Bac
AMP
Dil 3
A5
B5
C5
D5
E5
F5
G5
H5

Bac
AMP
Dil 4
A6
B6
C6
D6
E6
F6
G6
H6

Media
only
A7
B7
C7
D7
E7
F7
G7
H7

Bac
Chloramphenicol
A8
B8
C8
D8
E8
F8
G8
H8

Bac
6M
NaOH
A9
B9
C9
D9
E9
F9
G9
H9

Media
only

Bac

Media
only

A10
B10
C10
D10
E10
F10
G10
H10

A11
B11
C11
D11
E11
F11
G11
H11

A12
B12
C12
D12
E12
F12
G12
H12

The 96-well plate reader, and its attached computer was turned on, and the
Molecular Devices SoftMax Pro® v.5 program was used to collect the data. The
wavelength was set 630 nm, the plate was inserted into the reader, and Optical Density
measurements were taken of all 96 wells simultaneously at various time points. In
between measurements, the plates were incubated on a shaking platform at 200 RPM
at 37°C. Plate readings were done every half hour for the first 3 hours after
incubation, and then read again after an overnight incubation. The data files were
saved both as X-PDA format (Softmax only) and open source/ASCII X.csv/x.txt
format that was imported into Microsoft® Excel for further analysis.
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3.5.2 Procedure for Antimicrobial peptide Hemolytic Assay Protocol
Whole human blood samples were drawn from 2 anonymous volunteers into 3.5 ml
tubes containing the anticoagulant Heparin to facilitate intact red blood cell isolation.
The samples were combined, gently mixed, spun down at 800 x g, the supernatant was
discarded, and the cells were resuspended with filter-sterilized PBS Buffer (100 mM
NaCl, 80 mM Na2HPO4, 20 mM NaH2PO4, pH 7.4). The washes were repeated until
the supernatant became clear. The washed RBCs were diluted with PBS Buffer to a
final concentration of 8% (v/v) of packed cells.
Table 6 shows a typical setup for a Hemolysis Assay. Red blood cells were tested
with a total of five different peptide dilutions. The initial peptide concentrations were
5 mg/ml (1.71 mM) for LM7-1 and 5 mg/ml (1.67 mM) for LM7-2. A positive
hemolysis control was made by mixing 750 μl of suspended RBC and 750 μl of
0.020% (v/v) aqueous Triton X-100® to osmotically lyse the RBCs. A negative
hemolysis control was made by mixing 750 μl of suspended RBC and 750 μl of PBS
buffer. All test samples were incubated with mild agitation at 37ºC. At selected time
points, up to 24 hours, a 60 μl aliquot of each sample was centrifuged at 4000 x g for
10 minutes to pellet the intact RBCs. 50 μl of the test sample supernatant was then
diluted tenfold with 450 μl of PBS Buffer, gently vortexed, and read on the
Spectrophotometer.
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Table 6: Typical Setup for a Peptide-induced Hemolysis Assay. The template
shows volumes utilized throughout the various experimental runs. All 5 tubes used a
standardized concentration of human RBC. The AMP amounts tested varied from
tube to tube, with the PBS buffer making up the difference in volume.

LM7-1 AMP
(5 mg/ml-1.71 mM)
or LM7-2 AMP
(5 mg/ml-1.67 mM)
(8% v/v) RBCs
PBS Buffer
100 mM
0.020% (v/v)
aqueous Triton X100®
Total Volume
AMP Concentration
RBC Concentration

1
50 μl

2
40 μl

3
20 μl

Tube
4
5
10 μl
1 μl

150 μl
100 μl

150 μl
110 μl

150 μl
130 μl

750 μl
740 μl

750 μl
749 μl

(+) Control

(-) Control

750 μl

750 μl
750 μl

750 μl

300 μl
833
μg/ml
4%

300 μl
666
μg/ml
4%

300 μl
333
μg/ml
4%

1500 μl
33.3
μg/ml
4%

1500 μl
3.33
μg/ml
4%

1500 μl

1500 μl

4%

4%

The Genesys 10UV Scanning UV-VIS spectrophotometer was warmed up for 30
minutes; a quartz cuvette, which contained PBS buffer as a blank, was inserted into
the device. After zeroing the spectrophotometer with the blank, the samples were
scanned at 419 nm, which was the largest absorbance peak found in soluble
hemoglobin, as shown in Figure 14. The percent hemolysis was calculated using the
formula below:
 AbsPeptide  AbsPBSBuffer 
 x100
% Hemolysis  
 Abs0.020% Triton X -100  AbsPBS 
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(1)

Figure 14: Multiwavelength scan of soluble Hemoglobin from 200-600 nm. In this
graph, absorbance is plotted against wavelength in nanometers. The peak maxima at
215 nm, 270 nm, 350 nm, and 414 nm were observed in both oxygenated and
deoxygenated hemoglobin. The peak maxima at 540 nm and 580 nm were specific to
oxygenated hemoglobin samples.

3.5.3 Data Analysis
The Antimicrobial 96-Well Plate Activity Assays were the only portion of the
thesis research done using replicate trials. All of the samples were run with 8
replicates except for the uninhibited bacterial growth samples (16 replicates) and the
Mueller-Hinton media only samples (32 replicates). Each dilution of peptide was
compared to the uninhibited bacterial growth using an unpaired Student’s T-test.
Differences were considered significant when P<0.05 (Mather, 1965).

50

CHAPTER 4

RESULTS
4.1 Solid Phase Peptide Synthesis
4.1.1 Solid Phase Peptide Synthesis Discussion
Solid Phase Peptide Synthesis (SPPS) is a technique which is used to create
peptides or alternative medications from amino acid building blocks synthetically,
without the need for cells, enzymes, or ribosome’s. Although the protected amino
acid building blocks are expensive, and the time needed for synthesis is a function of
peptide length, SPPS offers several advantages over enzymatic synthesis. SPPS does
not take place in living cells, so it avoids the problem of separating the product
proteins from the rest of the cellular proteins, the issue of the formation of proteins
toxic to the synthesizing organism is avoided, and there are no uncertainties about the
contents of the reaction mixtures. It is also easy to incorporate unnatural amino acids
and post translational modifications during SPPS, which are more difficult to achieve
during peptide synthesis in vivo.
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4.1.2 Solid Phase Peptide Synthesis of Peptide LM7-1
Table 7: Summary of SPPS Coupling Reactions for Peptide LM7-1. This table
shows how many rounds of coupling reactions were required to complete the 27residue synthetic peptide. The AA position numbers started out at the N-terminal. As
shown in the middle 3 columns, some Boc amino acids required more than one round
of coupling to fully saturate the free amino groups. Eq is equivalents; it indicated how
much excess Boc-amino acids were added on each round of coupling relative to the
original amount of free amino groups on the resin. AA (mmol) indicated the actual
amounts of amino acids used for each coupling reaction. The end dates indicated
when an incoming Boc amino acid had fully coupled. Coupling number was the order
in which the Boc amino acids were added to the peptide-resin chain; as the synthesis
order was reversed from that of enzymatic biosynthesis.
AA
Position
27

AMINO
ACID
C-term NH2
N

Eq
1.0
0.4

aa
(mmol)
0.669
0.3

Eq

aa
(mmol)

4.0

2.7

26

L

5.0

3.4

25

Y

5.0

3.4

24

H

5.0

3.3

2.0

1.4

23

T

5.0

3.4

2.0

22

L

5.0

3.4

2.0

21

A

5.0

3.4

20

A

5.0

3.4

19

K

5.0

3.3

18

G

5.0

3.3

17

V

5.0

3.4

2.0

1.4

4.0

16

H

5.0

3.4

2.0

1.3

1.0

15

G

5.0

3.3

2.0

1.3

14

G

5.0

13

V

5.0

12

H

5.0

3.3

11

A

5.0

3.3

10

A

5.0

3.4

2.0

1.3

9

K

5.0

3.3

2.0

1.3

8

K

5.0

3.3

2.0

1.3

7

L

5.0

3.4

2.0

1.3

6

M

5.0

3.4

5

T

5.0

3.3

2.0

1.4

4.0

4

K

5.0

3.3

2.0

1.4

4.0

3

W

5.0

3.1

2

L

5.0

1

A

5.0

2.0

End
Date
7/3/09

Coupling

7/6/09

2

7/7/09

3

7/8/09

4

1.4

7/9/09

5

1.3

7/9/09

6

7/13/09

7

7/13/09

8

1.3

Eq

0.9

1

7/15/09

9

7/15/09

10

2.7

7/15/09

11

0.7

7/17/09

12

7/21/09

13

3.3

7/21/09

14

3.4

7/21/09

15

7/22/09

16

7/22/09

17

7/22/09

18

7/23/09

19

7/24/09

20

9/22/09

21

9/30/09

22

2.7

10/6/09

23

2.7

11/19/09

24

11/22/09

25

3.4

11/24/09

26

3.5

12/1/09

27

1.0

4.0

aa
(mmol)

0.2

52

1.0

0.7

The summary of the coupling reactions used to synthesize peptide LM7-1 is
summarized in Table 7. The 1-hydroxybenzotriazole (HOBt) protocol was the first
procedure used to couple the initial Asn27 (N-Boc-L-Asn-OH) to the amino-linked
beads in the MBHA resin. A racemic suppressor such as HOBt was important because
it prevented the incoming Boc-AA from base-catalyzed chirality inversion during an
extended overnight reaction. Figure 15 shows the possible sites for nucleophillic
attack of the lone pair electrons on a free N-terminus amino group on two possible
coupling reagents. Path 1 shows the electrons attacking the carbon in the ester group
contained within the O-acylisourea functional group. This is the intended site of
attack, as the Boc-AA will couple to the free amino group, and the DCU leaving group
will be removed. Path 2 shows an alternate site of attack; the electrons can attack the
α-carbon on the Boc-AA, due to the strong electron withdrawing potential of the Oacylisourea group. The loss of the hydrogen on the α-carbon can cause the Boc-AA to
potentially reverse chirality before the DCU is removed. Path 3 shows the electrons
attacking the carbon in the ester group contained within the HOBt active ester
functional group. This is the intended site of attack, as the Boc-AA will couple to the
free amino group, and the HOBt leaving group will be removed. Path 4 shows an
unlikely alternate site of attack; the electrons are less likely to attack the α-carbon on
the Boc-AA, due to the reduced electron withdrawing potential of the
oxybenzotriazole group. The initial coupling reaction was inadvertently run 10 times
less concentrated than necessary, so it was redone using a higher concentration of the
initial Boc-AA. The HOBt protocol used the standard N, N’53

dicyclohexylcarbodiimide (DCC) coupling agent, paired with an equimolar amount of
the protected amino acid and HOBt.

Figure 15: Advantages of 1-hydroxybenzotriazole over O-acylisourea as a
racemization suppressor. This figure shows the possible sites for nucleophillic
attack of the lone pair electrons on a free N-terminus amino group on two possible
coupling reagents. Path 1 shows the preferred location of attack for the amine group
lone pair electrons to the carbonyl in the O-acylisourea functional group, leading to
peptide extension. Path 2 shows an alternate site of attack; the O-acylisourea group
can draw electrons away from the α-carbon on the Boc-AA, potentially leading to
chirality inversion. Path 3 shows the preferred location of attack for the amine group
lone pair electrons to the carbonyl in the HOBt active ester functional group, leading
to peptide extension. Path 4 shows an unlikely alternate site of attack; the
oxybenzotriazole group has reduced electron withdrawing potential compared to the
O-acylisourea group. Thus, the electrons are less likely to attack the α-carbon on the
Boc-AA.

All of the couplings after the attachment of the first Boc-AA to the resin always
started with the Direct DCC catalyzed coupling protocol. It used a fivefold excess of
DCC with an equimolar amount of Boc-AA. The DCC reacted to the acidic end of the
Boc-AA and made a reactive leaving group that made it far easier for the amino acid
to form an amide bond. The DCC ended up as the waste product dicyclohexlurea
(DCU).
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The next two residues, Leu26 (N-Boc-L-Leu-OH), and Tyr25 (N-Boc-L-Tyr(OBzl)OH), coupled with the Direct DCC method. Tyrosine is a Boc-AA that frequently
possesses side chain protection, especially during the synthesis of long peptide chains.
The hydroxyl group on the side chain has a pKa of around 10, so it is vulnerable to
acylation by TFA or a Boc-AA. Having a Benzyloxy (OBzl) group reduces the
chance of acylation, or of the unwanted side reaction of migration of an acyl group to
the ortho position on the tyrosine ring.
Direct DCC was insufficient to drive the His24 (N-Boc-L-His(2,4-DNP)-OH)
reaction to completion, as the remaining free amino groups still produced a positive
blue pigment during the ninhydrin test. The His24 Boc-AA is a bulky residue, and
difficult to dissolve in DMF, especially with the 2,4-dinitrophenol (2,4-DNP) side
chain protecting group attached. The 2,4-DNP group is necessary due to the fact that
the unprotected side chain of histidine has a pKa around 6; the aromatic ring is
vulnerable to alkylation, and the electron withdrawing imidizole side chain can lead to
racemization. With the protecting group attached, the pKa is lowered to around 3, and
the residue side chain is stable during SPPS. Whenever the Direct DCC coupling
protocol failed, the Symmetric Anhydride protocol was subsequently employed to
completely eliminate any remaining free amino termini.
During the process of utilizing the Symmetric Anhydride protocol, the DCC
coupling reagent did not directly catalyze the attachment of the Boc-AA to the
peptide-resin. The alternate reaction mechanism was that one equivalent of DCC was
used to couple two equivalents of the Boc-amino acid to each other to form a
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symmetric anhydride. In the next step of the reaction, the anhydride reacted with the
amino end of the peptide to form a slightly longer chain, with one Boc-AA bonding to
the chain, and the other ending up as soluble waste along with the DCU. Symmetric
anhydrides are extremely reactive, and are effective at coupling sterically hindered or
insoluble residues. However, this reaction is never used before Direct DCC for
several reasons: half of the Boc-AA reagent is wasted, and at elevated temperatures,
the Symmetric Anhydride can react intramolecularly to produce a double Boc-AA
coupling. Thr23 (N-Boc-L-Thr(OBzl)-OH) and Leu22 (N-Boc-L-Leu-OH) also
required a combination of direct DCC and symmetric anhydride couplings to be
effective.
Residues Ala21 (N-Boc-L-Ala-OH) and Ala20 (N-Boc-L-Ala-OH) coupled
satisfactorily with the Direct DCC Catalyzed Coupling Protocol. The next residue,
Lys19 (N-Boc-L-Lys(2-Cl-Z)-OH) did not couple completely with the Direct DCC
catalyzed coupling protocol, or Symmetric Anhydride coupling protocol because this
yielded positive ninhydrin results. Therefore, the HOBt coupling protocol was used to
complete the Boc-AA attachment. This was the same HOBt Coupling Protocol that
was used to attach the initial Asn27 residue to the resin. Although the side chain
protection on lysine adds to its bulk and reduces solubility in DMF, lysine is a BocAA residue that must always be protected during SPPS. A lysine with an exposed side
chain amino group can couple with incoming Boc-AAs, creating branched peptides.
During this peptide synthesis, 2-chloro-benzyloxycarbonyl (2-Cl-Z) was selected in
place of benzyloxycarbonyl (Bzl) as the lysine side protection. Benzyloxycarbonyl,
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like tert-butyloxycarbonyl (Boc) is labile to TFA cleavage. Adding chlorine to the Bzl
group in the ortho position reduces side chain protection losses significantly.
During the remainder of the sequence, Gly18 (N-Boc-Gly-OH), Gly14 (N-Boc-GlyOH), Val13 (N-Boc-L-Val-OH), Ala11 (N-Boc-L-Ala-OH), Met6 (N-Boc-L-Met-OH),
Trp3 (N-Boc-L-Trp-OH), Leu2 (N-Boc-L-Leu-OH), and Ala1 (N-Boc-L-Ala-OH) all
coupled in a single reaction with the initial Direct DCC Protocol. With the exception
of Tyr25, and Trp3, which were largely aromatic, all the residues that coupled with the
first protocol had short chain aliphatic hydrocarbon side chains. Thus, these types of
residues were easier to dissolve into solution. None of these residues had side chain
protection, as hydrophobic side chains are not susceptible to undesired side reactions.
Two coupling protocols were needed for Gly15 (N-Boc-Gly-OH), His12 (N-Boc-LHis(2,4-DNP)-OH), Ala10 (N-Boc-L-Ala-OH), Lys8 (N-Boc-L-Lys(2-Cl-Z)-OH), and
Leu7 (N-Boc-L-Leu-OH). Although four of the total residues that coupled on the
second protocol were aliphatic, two were polar, and three were positively charged.
This seems to indicate that residues with polar and positively charged side chains were
more difficult to couple to the peptide chain than other side chain types.
Three coupling protocols were needed for Val17 (N-Boc-L-Val-OH), His16 (N-BocL-His(2,4-DNP)-OH), Lys9 (N-Boc-L-Lys(2-Cl-Z)-OH), Thr5 (N-Boc-L-Thr(Bzl)OH), and Lys4 (N-Boc-L-Lys(2-Cl-Z)-OH). Threonine, like histidine and lysine, is
another Boc-AA that requires side chain protection. Unprotected hydroxyl groups in
threonine and serine can react with an adjacent amide group to transfer part of the
peptide chain onto the side chain, creating an ether linkage. Having a Benzyloxy
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(OBzl) group attached blocks this undesired side reaction, although it increases mass
and reduces Boc-AA solubility in DMF. Only one of the total residues that coupled
on the third protocol were aliphatic, one was polar, and the remaining three were
positively charged. This seems to indicate that residues with polar and positively
charged side chains were more difficult to couple to the peptide chain than other side
chain types.
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4.1.3 Solid Phase Peptide Synthesis of Peptide LM7-2
Table 8: Summary of Coupling Reactions for Peptide LM7-2. This table shows
how many rounds of coupling reactions were required to complete the 27 residue
synthetic peptide. The AA positions started out at the N-terminus. As shown in the
middle 3 columns, some Boc amino acids required more than one round of coupling to
fully saturate the free amino groups. Eq is equivalents; it indicated how much excess
Boc-amino acids were added on each round of coupling relative to the original amount
of free amino groups on the resin. AA (mmol) indicated the actual amount of amino
acids used for each coupling reaction. The end dates indicated when an incoming Boc
amino acid had fully coupled. Coupling number was the order in which the Boc
amino acids were added to the peptide-resin chain as the synthesis order was reversed
from that of enzymatic biosynthesis.
AA
Position
27

AMINO
ACID
C-term NH2
N

Eq
1.0
4.0

aa
(mmol)
0.669
0.8

Eq

aa
(mmol)

2.0

0.4

26

L

5.0

0.9

25

Y

5.0

0.9

24

H

5.0

0.9

2.0

0.4

23

T

5.0

0.9

2.0

22

L

5.0

0.9

2.0

21

A

5.0

20

A

19

K

18

End
Date
1/7/11

Coupling

1/13/11

2

1/13/11

3

1/23/11

4

0.4

1/30/11

5

0.4

2/3/11

6

0.9

2/15/11

7

5.0

0.9

2/23/11

8

5.0

0.9

2/25/11

9

G

5.0

0.9

3/2/11

10

17

V

5.0

0.9

3/4/11

11

16

H

5.0

0.9

3/6/11

12

15

K

5.0

0.9

3/12/11

13

14

G

5.0

0.9

2/21/11

14

13

V

5.0

0.9

3/26/11

15

12

H

5.0

0.9

3/28/11

16

11

A

5.0

0.9

3/30/11

17

10

A

5.0

0.9

3/30/11

18

9

K

5.0

0.9

4/1/11

19

8

K

5.0

0.9

4/3/11

20

7

L

5.0

0.9

4/4/11

21

6

M

5.0

0.9

4/6/11

22

5

T

5.0

0.9

4/6/11

23

4

K

5.0

0.9

3

W

5.0

0.9

2

L

5.0

1

A

5.0

2.0

2.0

0.4

Eq

4.0

aa
(mmol)

Eq

aa
(mmol)

0.7

0.4

1

4/8/11

24

4/27/11

25

0.9

4/27/11

26

0.9

5/1/11

27

2.0

0.4

4.0
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0.7

5.0

0.9

The summary of the coupling reactions used to synthesize peptide LM7-2 is
summarized in Table 8. LM7-2 was synthesized under identical conditions to LM7-1
using the same reagents, resin and equipment. Asn27 (N-Boc-L-Asn-OH), required the
HOBt and Symmetric Anhydride protocols to complete the coupling.
For every Boc-AA residue after that, the Direct DCC Catalyzed Coupling protocol
was always used first. Leu26 (N-Boc-L-Leu-OH), Tyr25 (N-Boc-L-Tyr(OBzl)-OH),
Ala21 (N-Boc-L-Ala-OH), Ala20 (N-Boc-L-Ala-OH), Lys19 (N-Boc-L-Lys(2-Cl-Z)OH), Val17 (N-Boc-L-Val-OH), His16 (N-Boc-L-His(2,4-DNP)-OH), Lys15 (N-Boc-LLys(2-Cl-Z)-OH), Gly14 (N-Boc-Gly-OH), His12 (N-Boc-L-His(2,4-DNP)-OH), Ala11
(N-Boc-L-Ala-OH), Ala10 (N-Boc-L-Ala-OH), Lys9 (N-Boc-L-Lys(2-Cl-Z)-OH), Lys8
(N-Boc-L-Lys(2-Cl-Z)-OH), Leu7 (N-Boc-L-Leu-OH), Met6 (N-Boc-L-Met-OH), Thr5
(N-Boc-L-Thr(OBzl)-OH), Lys4 (N-Boc-L-Lys(2-Cl-Z)-OH), Leu2 (N-Boc-L-LeuOH), and Ala1 (N-Boc-L-Ala-OH) all coupled with the initial Direct DCC Protocol.
Eleven of the residues had short aliphatic hydrocarbon side chains, one was aromatic,
one was polar, and seven were positively charged. The amino acids with aliphatic side
chains tended to be the easiest to couple, as they did not require side chain protection,
and were soluble in DMF. The residues with bulky side chain protection coupled
easily due to the fact they were not in a disadvantageous position in the sequence.
Two coupling protocols were needed for His24 (N-Boc-L-His(2,4-DNP)-OH), Thr23
(N-Boc-L-Thr(OBzl)-OH), Leu22 (N-Boc-L-Leu-OH), and Val13 (N-Boc-L-Val-OH).
Two of the total residues that coupled on the second protocol were aliphatic, two were
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polar, and one was positively charged. Two of the three residues had bulky side chain
protection, so it is not surprising that they were more difficult to couple.
Three coupling protocols were needed for Gly18 (N-Boc-Gly-OH). This can be
potentially explained by being in a disadvantageous position in the sequence. LM7-1
had a similar coupling difficulty one residue over.
Four coupling protocols were needed for Trp3 (N-Boc-L-Trp-OH). The 2-(1Hbenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)
protocol was used due to the failure of the first three protocols. To begin, the HBTU
protocol reacted with the Boc-AA using a two step mechanism, and produced a highly
reactive leaving group to fully couple the Boc-AA to the peptide chain. The residue
that coupled had an aromatic side chain. Trp3 in LM7-1 coupled on the first try, so it is
likely that there was difficulty in one of the solvents used during the coupling reaction.
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4.1.4 Comparison of Coupling Efficiency of Peptide LM7-1 versus LM7-2
Table 9: Coupling Efficiency of LM7-1 versus LM7-2. This graph compares how
many repeated couplings were required in order to completely attach incoming BocAA onto the growing peptide chains of LM7-1 (Blue bars) and LM7-2 (Violet bars).
The number of coupling repetitions needed is plotted against peptide sequence
numbers from the N-terminus to the C-terminus.

Number of Coupling Repetitions Needed

4

3

LM7-1
LM7-2

2

1
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Coupling Number

The AMPs LM7-1 and LM7-2 only differed in a single residue; Lys15 in LM7-2
was replaced with Gly15 in AMP LM7-1. As shown in Table 9, although there was
only one amino acid substitution, there were a variety of differences between the two
sequences. LM7-1 had fifteen residues out of twenty seven that required multiple
couplings. Upon surveying the results, it was noted that the majority of the “difficult”
residues were polar and positively charged; this suggests that those properties
increased the difficulty of Boc-amino acid attachment. However, LM7-2 only had
seven residues out of twenty seven that required multiple coupling attempts. The side
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chain types in LM7-2 were balanced, so no overall pattern can be inferred. With one
exception, LM7-1 and LM7-2 had identical AA sequences. Thus, it was likely in the
areas where the number of required couplings did not match between the two AMP
sequences, that refinement of experimenter technique was responsible for the results,
and not the intrinsic difficulty in coupling the sequences themselves. Near the Cterminus of the peptides, at residues His24, Thr23, and Leu22 the number of repeated
coupling steps was the same for both peptides. This implies that the “initiation” region
of SPPS possessed the greatest difficulty in attaining full couplings. This finding
makes intuitive sense as the initial residues were located closest to the solid resin
support, so they would be expected to be the most sterically hindered. Alternatively,
this difficulty could possibly be due to the formation of an alpha-helical type in the
highly conserved C-terminal sequence, despite the lack of an aqueous solvent during
SPPS.
4.2 Liquid Chromatography
4.2.1 Liquid Chromatography Overview
Liquid Chromatography is a purification technique which is used to separate out
the desired pure peptide product from shorter failure peptide sequences, and all other
contaminants. When proteins are manufactured by SPPS and cleaved off the resin
support, chemical contaminants must be first removed so that the product peptide can
be thoroughly purified. The two types of liquid chromatography listed below are
usually sufficient for synthetic peptide purification for antimicrobial assays when used
sequentially. Gel filtration liquid chromatography is used to separate protein products
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from synthesis reagents and byproducts immediately following HF resin-cleavage.
Preparatory Reversed Phase High Performance Liquid Chromatography is then used to
isolate the pure peptide. The purity of the peptide is assessed with Mass
Spectrometry, and then the isolated peptide can be used in antimicrobial assays and
other tests.
4.2.2 Gel Filtration Liquid Chromatography Discussion
Sephedex® is a dextran derived, cross-linked mixture of polysaccharide beads that
are manufactured at varying pore sizes to exclude all analytes above a certain cutoff
volume; all biopolymers below this cutoff are retained in inverse proportion to their
overall hydrated volume. In this case, G25 Sephedex® will typically exclude the
AMPs above the 5 kDa range, and retain the low mass scavengers and reagents left
over following the HF cleavage step. For many peptides, the use of this
polysaccharide stationary phase after Solid Phase Peptide Synthesis will separate the
peptide from other synthesis by products, and yield an adequately pure sample for
biological studies.
4.2.3 Gel Filtration Liquid Chromatography Results
It was observed that both crude product peptides LM7-1 and LM7-2 behaved very
similarly during preliminary purification on the Gel Filtration Chromatography
column, which was run after the final side chain deprotection peptide-resin cleavage
steps were completed. The yellow mixture of peptides and synthesis by products
rapidly transited the column and separated out into two visible yellow bands. The
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eluent was monitored by UV detection, at 280 nm and 300 nm; which also indicated a
two peaked chromatogram which was divided into Peak A and Peak B pools for
further analysis. As the G25 column stationary phase was designed to exclude >5kDa
peptides such as LM7-1 and LM7-2, these products traveled unrestrained through the
column and eluted directly after the void mobile phase volume had passed through the
apparatus. The leading edge and peak region of Peak A, as seen in Figure 16, likely
contained the purest peptide sample. The tailing end of Peak A was assumed to
contain a mixture of pure peptide and possibly shorter failure sequences. The B Peak
Region contained very little full-length peptide, and consisted of a large proportion of
synthesis waste by products.

Figure 16: LM7-1 Crude Peptide Eluent G-25 Sephedex® Gel Filtration Run.
This graph shows a representative liquid chromatography run that passed a crude
LM7-1 AMP wash sample through a 2.5 x 86.0 cm bed of G25 Sephedex® at a flow
rate of 0.6 ml/min. The graph compares absorbance at 280 nm versus Fraction
number. Note that there are two peaks: the purified LM7-1 Peak A (Fractions 110143), and the HF scavenger Peak B (Fractions 144-160).
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As the concentration of dissolved peptide in the post hydrofluoric acid cleavage
protocol 10% acetic acid wash was low, and the subsequent runs used concentrated
solutions prepared from dried crude peptide product. This is shown in Figure 17.
Again, the two yellow bands were visibly resolved in the column, although the larger
concentration of peptides in the eluent maxed out the UV detector used to monitor
peaks during the chromatogram run. When necessary, fraction tubes that showed
maximized absorbance on the UV flow cell were removed, diluted, and individually
run on a spectrophotometer to determine precisely where the pure peptide peak (with
the largest peptide bond absorbance) was precisely located.

Figure 17: LM7-1 Crude Peptide Product G-25 Sephedex® Gel Filtration Run.
This graph shows a crude peptide liquid chromatography run that passed a crude
LM7-1 AMP 10% acetic acid extraction sample through a 2.5 x 86.0 cm bed of G25
Sephedex® at a flow rate of 0.6 ml/min. Based on the results shown in Figure 11, the
first 80 fractions were discarded and then the remaining fractions were recorded and
collected for analysis. The graph compares absorbance at 280 nm versus Fraction
number. Note that there are two peaks: the purified LM7-1 Peak A (Fractions 12-41),
and the HF scavenger Peak B (Fractions 42-80). As the peptide was concentrated to
~25 mg/ml, the absorbance of the middle of the peaks maxed out the UV detector.
Exact peak boundaries were determined by scanning the diluted samples in the off
scale regions.
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4.2.4 Preparatory High Performance Liquid Chromatography Discussion
Reversed Phase High Performance Liquid Chromatography (RP-HPLC) is a high
resolution separation technique that can be used to purify many different types of
chemicals. When used for proteomic applications, the main focus of these applications
is on short peptides from 4-40 amino acid residues in length. RP-HPLC uses a nonpolar stationary phase paired with a more polar mobile phase. The stationary phase
contains silica beads with covalently bonded C18 hydrocarbon chains to present a
hydrophobic surface for the analyte to adsorb. The mobile phase is mixture of polar
water, nonpolar acetonitrile and the hydrophobic counterion trifluoroacetic acid
(TFA). The pressurized mixture is pumped in through a control valve, into the base of
the column, up out through the top, and then through a UV detector to a fraction
collector. Initial conditions for RP-HPLC include a mobile phase of 5%
acetonitrile/95% water/0.1% TFA. Under these conditions the injected peptide and
associated synthesis byproducts will adsorb tightly to the C18 hydrocarbon chains
within the stationary phase. During a run, the amount of acetonitrile is increased by
incremental steps. When the mobile phase hydrophobicity, increases to the point that
it matches a component of the sample, the product will then partition into solution and
elute off the column and into the mobile phase. Because no two components in a
sample mixture have identical hydrophobicities; under the correct gradient conditions,
complex multi-peptide mixtures can be eluted as separate purified peaks.
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4.2.5 Preparatory High Performance Liquid Chromatography on a C18 Reversed
Phase Column Results
Both LM7-1 and LM7-2 AMPs were run through a RP- HPLC C18 column that
used an acetonitrile/water/TFA mobile phase. By ramping up the acetonitrile (ACN)
concentration in discrete steps, substances of increasing hydrophobicity eluted as
separate peaks. For LM7-1, the exact character of the hydrophobicity of the crude
Peptide Peak A was unknown. Thus, small samples were then run through the prep
column as to develop a method which produces a maximum number of peaks with
baseline resolution during a given run.
Figure 18 shows an early example of a peptide run through a preparative RP-HPLC
column with only three mobile-phase gradient steps, and they were characterized by
the following mixtures of acetonitrile and water, with 0.1% TFA as an ion-pairing
additive: 20% acetonitrile (0:00-22:00 min), 35% acetonitrile (22:01-40:00 min), and
40% acetonitrile (40:00-55:00 min). There was a final wash step of 100% methanol
(55:01-66:00 min). Only four peaks were noted in the resulting chromatogram, and
the middle two were poorly resolved. The larger peaks had several components
hidden within them, as the mass spectroscopy results indicated that none of the eluted
peaks contained a single mass.
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Figure 18: LM7-1 Purified by HPLC Preparative Reversed Phase HPLC with a
three-step acetonitrile gradient (Run 4). The purified Peak A-2 region (Run # 4) of
the LM7-1 AMP eluent from the G-25 column was run through a C18Vydac
preparatory, RP-HPLC column (300Å, 2.2 x 25.0 cm, 218 TP) to purify the desired
peptide before running bioassays. The flow rate was 2.9 ml/min. The mobile phase
gradient consisted of 20%, 35%, and 40% aqueous acetonitrile, followed by a 100%
methanol column wash. The graph plots absorbance at 280 nm versus Fraction
number.
Figure 19 shows an example of a preparatory Reversed phase HPLC peptide run
with six steps in the gradient, and they were characterized by the following mixtures
of acetonitrile and water: 5% acetonitrile (0:00-15:00 min), 20% acetonitrile (15:0118:00 min), 25% actonitrile (18:01-25:00 min), 35% acetonitrile (25:01-40:00 min),
40% acetonitrile (40:01-52:00 min), and 70% acetonitrile (52:01-66:00 min). Eight
peaks were noted in the resulting chromatogram, and only two of them contained
multiple masses. Mass spectroscopy analysis of these peaks indicated the presence of
complex samples, indicating that further HPLC methods development should be done
to further resolve the hidden peaks.
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Figure 19: LM7-1 Purified by Preparative Reversed Phase HPLC with a six-step
acetonitrile gradient (Run 14). The purified Peak A-2 region (Run 14) of the LM7-1
AMP eluent from the G-25 column was run through a C18Vydac preparatory
RP-HPLC column (300Å, 2.2 x 25.0 cm, 218 TP). The mobile phase gradient
consisted of 5%, 20%, 25%, 35%, 40% and 70% aqueous acetonitrile. The flow rate
was 2.9 ml/min. The graph plots absorbance at 280 nm versus Fraction number.

Figure 20 shows an example of a preparative RP-HPLC run with six steps in the
gradient: 5% acetonitrile (0:00-12:00 min), 20% acetonitrile (12:01-18:00 min), 25%
acetonitrile (18:01-22:00 min), 30% acetonitrile (22:01-42:00 min), 35% acetonitrile
(42:01-58:00 min), and 70% acetonitrile (58:01-66:00 min). There are eight peaks,
and only two of them remain poorly resolved. Most notably, several of the peaks
contained only a single peptide based on mass spectroscopy results. The RP-HPLC
purification method for this peptide was deemed optimized, and similarly eluting
peaks were then pooled for both peptides LM7-1 and LM7-2.
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Figure 20: LM7-1 Purified Preparative Reversed Phase HPLC with a six-step
acetonitrile gradient (Run 18). The purified Peak A-2 region (Run 14) from the
LM7-1 AMP was run through a C18Vydac preparatory RP-HPLC column (300Å, 2.2 x
25.0 cm, 218 TP). The mobile phase gradient consisted of 5%, 20%, 25%, 30%, 35%
and 70% aqueous acetonitrile. The flow rate was 2.9 ml/min. The graph plots
absorbance at 280 nm versus Fraction number.

4.3 Mass Spectroscopy
4.3.1 Matrix Assisted Laser Desorption Ionization-Time of Flight Discussion
Matrix Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) is a
gentle and accurate mass spectrometry technique used to determine the charge/mass
ratio for intact peptides. Mass spectrometry requires ionization of sample molecules,
which must enter the gas phase so they can be accelerated into a trajectory that
migrates along the TOF detector tube based on the relative mass/charge ratios.
MALDI, unlike many other forms of mass spectrometry, ionizes large peptides
without fragmenting them. The peptide samples are first dried in a laser-absorbing
matrix that surrounds the sample molecules. The matrix protects the peptide from the
laser, and so the peptide is ejected into the gas phase in an intact form. The exact time
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required for ions to travel through a long tube before they hit the detector provides
accurate m/z data.
4.3.2 Matrix Assisted Laser Desorption Ionization-Time of Flight Results and
Sample Pooling
Table 10 shows the Ciphergen SELDI protein chip mass spectroscopy results. All
the dried LM7-1 peptide fractions from the prep HPLC runs were subjected to a
second round of pooling peptides according to similar mass composition. The three
pooling categories were: pure peptides, impure peptides and peaks containing nontarget sequences. The first column of Table 10 has the label used for the 3 sample
types: 1/P-FR (Pure Fractions), 2/IMP-FR (Impure Fractions), and 3/JK-FR (Junk
Fractions). The masses listed indicate the approximate target mass/charge used to
determine where each sample was to be pooled. The second column indicates all the
observed mass/charge ratios observed, rounded to the nearest Dalton/z. The third
column indicates which dried peptide samples from prep RP-HPLC runs were
combined to make each of the three final peptide pools. The three symbol code refers
to previously pooled peptides, the longer code indicates individual peptide fractions,
and the waste code indicates that some peptides were indeed isolated from non-peak
regions. The forth column indicates the estimated yield (by visual inspection) of the
lyophilized final peptide pools, ready for biological assays.
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Table 10: MALDI Results and Sample Pooling for LM7-1. The Peptide Rank label
indicates how pure the pooled peptide samples were based on MALDI-TOF mass
spectrometry results. The Observed m/z indicates the observed mass charge ratios.
The Dried Peptide indicates where the samples originated from. The estimated mass
of the purified samples is based on visual inspection.
Pure
Peptide
Rank/Label
1/P-FR
2912
2934/2970
2/IMP-FR
2912
2934/2970
3000+

3/JK-FR
Everything
except:
2912
2934/2970

Observed m/z

Dried Peptide

Estimated
Mass

2912, 2913, 2914,
2915, 2934, 2936,
2937, 2970, 2971
2910, 2911, 2912,
2913, 2914, 2915,
2929, 2932, 2933,
2934, 2936, 2967,
2968, 2969, 2970,
2971, 3000, 3002,
3004, 3005, 3034,
3038, 3050, 3058,
3060, 3108, 3106,
3110, 3124, 3140
1725, 1980, 2854,
2985, 3000, 3007,
3017, 3034, 3035,
3036, 3077, 3079,
3091, 3093, 3094,
3116, 3118, 3123,
3126, 3128, 3169,
3174, 3185

6A-3, 6A-4, 6B-1, 6B-2, 6B-5,
A-2-17C (P84), A-2-17H (P89),
A-2-18C (P92)
2B-2, 6B-3, 6B-4, A-2-17D (P85),
A-2-17E (P86), A-2-17F (P87),
A-2-17G (P88), A-2-18D (P93),
A-2-18E (P94), A-2-19C (P99),
A-2-19D (P100), A-2-19E (P101),
A-2-19F (P102), A-2-19G
(P103A), Waste 6, Waste 9

~15 mg
~95 mg

4A-2, 6A-5, A-2-17A (P82),
~55 mg
A-2-18A (P90), A-2-18B (P91),
A-2-18F (P95), A-2-18G (P96),
A-2-19A (P97), A-2-19G (P103B),
A-2-19H (P104), A-2-19I (P105),
Waste 7, Waste 8, Waste 10

Table 11 shows the LM7-2 pooling results. Determining the mass of the peptides
purified during preparatory HPLC runs for LM7-2 was difficult due to the lack of
usable results from the INBRE core lab’s new instrument, the Shimazu Axima
MALDI-TOF, so the samples were simply pooled by HPLC elution times instead.
The first column in Table 11 has the labels for the 8 sample patterns obtained from the
LM7-2 prep HPLC runs: Peak A, Peak B, Peak C, Peak D (peak leading edge and
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top), Peak D tail (peak tail), Peak E (peak leading edge and top), Peak E tail (peak
tail). Any samples that did not yield peptide sample after lyophilization were counted
as discards. The second column indicates which dried peptide samples were combined
to make the eight pooled peptide samples. The third column indicates the mass of the
pooled, and lyophilized peptide fractions.
Table 11: Sample Pooling for LM7-2. The Peptide Rank label indicates how the
peptide samples were pooled based on RP-HPLC peak elution order. The Dried
Peptide indicates which HPLC runs the samples originated from that were combined
on the final pools. The estimated yields of the purified peptides were defined by
weighing them on an electronic balance.
Pure
Peptide
Rank/Label
LM7-2
Peak A
LM7-2
Peak B
LM7-2
Peak C
LM7-2
Peak D
LM7-2
Peak D
tail
LM7-2
Peak E
LM7-2
Peak E
tail
LM7-2
Discards

Dried Peptide

Mass

A-7A (P30)

1.0 mg

A-1A tail (P1-2), Pre A-2B (P6-), A-2B (P6),
A-3B (P11), Pre A-4B (P16-), A-4B (P16),
Pre A-5B (P21-), A-5B (P21), Pre A-6B (P26-),
A-6B (P26)
A-1B (P2), A-1B tail (P2-3), A-2C (P7), A-3C (P12),
A-4C (P17), A-5C (P22), A-6C (P27), A-7C (P32)
A-1C (P3), A-2D (P8), A-3B (P13), A-4D (P18),
A-5D (P23), A-6D (P28), A-7D (P33)
A-1C tail (P3-4), A-2D tail (P8-9), A-3D tail (P13-14),
A-4D tail (P18-19), A-5D tail (P23-24),
A-6D tail (P28-29), A-7D tail (P33-34)
A-1D (P4), A-2E (P9), A-3E (P14), A-4E (P19),
A-5E (P24), A-6E (P29), A-7E (P34)
A-1D tail Fr (P4+), A-1D tail pool (P4+),
A-2E tail Fr (P9+), A-3E tail (P14+), A-4E tail (P19+),
A-5E tail (P24+), A-6E tail (P29+), A-7E tail (P34+)
Pre A-1A (P1-), A-1A (P1), Pre A-2A (P5-),
A-2A (P5), A-2E tail pool (P9+), Pre A-3A (P10-),
A-3A (P10), Pre A-3B (P11-), Pre A-4A (P15-),
A-4A (P15), Pre A-5A (P20-), A-5A (P20),
Pre A-6A (P25-), A-6A (P25), Pre A-7A (P30-),
Pre A-7B (P31-), A-7B (P31)

0.6 mg
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1.5 mg
2.7 mg
7.1 mg
13.9 mg
21.9 mg
-

4.3.3 Liquid Chromatography-Electrospray Ionization-Mass Spectrometry
Discussion
Liquid Chromatography-Electrospray Ionization-Mass Spectrometry (LC-ESI-MS)
is an accurate mass spectrometry technique used to determine charge/mass ratio for
peptides and other analytes. The samples are typically injected into a LC column that
resolves the sample into separate peaks, which individually enter into the mass
spectrometer. This technique also acts as a check for purity, as fewer peaks indicate
less contamination in the sample. Once in the spectrometer, the samples are ionized
by an evaporation nebulizer and accelerated in an electric field. As they circle in a
vacuum chamber around an electrode in the detector area, their characteristic
frequency can be measured to determine their m/z ratios. Differing numbers of
positive charges on an identical the peptide sample yield a closely related family of
m/z ratios that can be deconvoluted to produce an overall mass for each peptide in the
sample.
4.3.4 Liquid Chromatography-Electrospray Ionization-Mass Spectrometry
Results
LM7-1 (1P-FR) and LM7-2 (Peak E) were subjected to Liquid ChromatographyElectrospray Ionization-Mass Spectrometry using a Linear Trap Quadropole Orbitrap
Velos Mass Spectrometer at the EPSCoR Brown University Proteomics lab.
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LM7-1 Results:
Calculated monoisotopic mass:

2913.63 Da

Observed m/z:

1457.825, 972.219, 729.416, 583.734,
486.615, 417.242, 365.211

Deconvoluted observed mass:

2913.638 (+/- 0.006) Da

Based on the LC-MS results, only a single major mass peak was isolated by prep
HPLC. All of the multiple-charged m/z peaks are consistent with a single peptide
mass of 2913.638 Da. As the calculated mass for the amino acid sequence of the
peptide and the measured masses were identical, this indicated the LM7-1 peptide was
successfully synthesized, and purified to homogeneity.
LM7-2 Results:
Calculated monoisotopic mass:

2984.70 Da

Deconvoluted observed mass:

2984.675 (+/- 0.001) Da
2914.633 (+/- 0.001) Da

Based on the LC-MS results, a major mass peak and a minor mass peak were
present in the peptide sample. The calculated mass of 2984.675 Da, based on the
desired amino acid sequence was the major observed product, along with a failure
sequence of mass 2914.633 Da that possessed a mass consistent with a product peptide
having a deleted alanine residue. As the calculated and measured masses were very
close for at least one of the AMPs in the product mixture, the LC-MS results indicated
that LM7-2 was mostly purified. However, the pooled peptide product tested in later
assays contained small amounts of a shorter failure sequence as well.
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4.4 Antimicrobial Activity Assay
4.4.1 Antimicrobial Activity Assay Discussion
A bioactivity assay is a method used to measure the ability of antibiotics and
antimicrobial peptides to inhibit bacterial growth in the log phase. Any diminishment
or elimination of normal bacterial growth indicates that the compound being assayed
is active against the test bacteria. A common type of screening assay examples is an
exponentially growing bacterial culture monitored in a 96-well plate. Overall bacterial
cell density is charted by measuring optical density (light scattering at 630 nm) using a
plate reader spectrophotometer to scan cultures over a 24 hour time course.
4.4.2 Antimicrobial Activity Assay Results
For comparison, graphs of the results of the antimicrobial assays against four
different bacterial strains all have the same general format. Not graphed were control
data showing the inhibition of bacterial growth in either chloramphenicol or NaOH.
The mean ODs of the Mueller Hinton media only scans was subtracted from all the
other data sets to eliminate the light scattering effect of the growth media itself prior to
graphing.

On the left side of each time point, the bar represents the OD of an

innoculum of bacteria in Mueller Hinton Broth which models unrestrained growth.
The next four bars show the effect of increasing concentrations of the manufactured
peptides. The time between monitoring steps was an interval of ~30 min, except for
prior to the last step, which was obtained at the 24 hour mark.
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The antimicrobial effectiveness of LM7-1 against the two gram negative bacterial
strains is shown: E.coli in Figure 21 and P.aeruginosa in Figure 22. These bacterial
species were chosen as they were frequently cited as human pathogens. In the E.coli
assay, all doses of the LM7-1 peptides were effective at inhibiting bacterial growth at
the 3 hour time point; the two higher doses of the LM7-1 peptides inhibited bacterial
growth at the 24 hour time point. In the P.aeruginosa assay, the two higher doses of
the LM7-1 peptides inhibited bacterial growth at the 2 hour time point; no doses of the
LM7-1 peptides inhibited bacterial growth at the 24 hour time point. This suggested
that LM7-1 was active against E.coli and P.aeruginosa for the first few hours of
incubation; however, LM7-1 was only active against E.coli at 24 hours post-treatment.
This data suggested that LM7-1 was effective against E.coli.
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Figure 21: Antimicrobial Activity Assay of LM7-1 against E.coli. The graph
shows Optical density at 630 nm versus time for exposure in hours. The red bars show
the uninhibited growth of the bacteria. The remaining bars (orange, green, blue and
violet) show the amount of bacterial inhibition observed with increasing
concentrations of peptide LM7-1. The error bars display one standard deviation of
variance. At the 24 hour time point, compared to the uninhibited E.coli growth (‡), the
0.333 μg/ml peptide trial shows a significant (*) difference [0.05>P>0.001], and the
167/333 μg/ml peptide dilutions show extremely significant (**) differences
[0.001>P] in bacterial growth.
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Figure 22: Antimicrobial Activity Assay of LM7-1 against P.aeruginosa. The
graph shows Optical density at 630 nm versus time for exposure in hours. The red
bars show the uninhibited growth of the bacteria. The remaining bars (orange, green,
blue and violet) show the amount of bacterial inhibition observed with increasing
concentrations of peptide LM7-1. The error bars display one standard deviation of
variance. At the 24 hour timepoint, compared to the uninhibited P.aeruginosa growth
(‡), the 167/333 μg/ml peptide trials show significant (*) differences [0.05>P>0.001]
in bacterial growth.

The antimicrobial effectiveness of LM7-1 against the two gram positive strains is
shown: E.faecalis in Figure 23 and S.aureus in Figure 24. These bacterial species
were chosen as they were frequently cited as human pathogens. In the E.faecalis
assay, the two most concentrated samples of the LM7-1 peptides were effective at
inhibiting bacterial growth at the 3 hour time point; the two higher doses of the LM7-1
peptides inhibited bacterial growth at the 24 hour time point. In the S.aureus assay,
the two higher doses of the LM7-1 peptides inhibited bacterial growth at the 3 hour
time point; only the highest dose of the LM7-1 peptides inhibited bacterial growth at
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the 24 hour time point. This suggested that LM7-1 was active against both E.faecalis
and S.aureus for the first few hours of incubation; however, LM7-1 only remained
active against E.faecalis at 24 hours post-treatment. This data suggested that LM7-1
was effective against E.faecalis.

Figure 23: Antimicrobial Activity Assay of LM7-1 against E.faecalis. The graph
shows Optical density at 630 nm versus time for exposure in hours. The red bars show
the uninhibited growth of the bacteria. The remaining bars (orange, green, blue and
violet) show the amount of bacterial inhibition observed with increasing concentration
of peptide. The error bars display one standard deviation of variance. In the 24 hour
timepoint, compared to the uninhibited E.faecalis growth (‡), the 0.333 μg/ml peptide
trial shows a significant (*) difference [0.05>P>0.001], and the 167/333 μg/ml peptide
trials show extremely significant (**) differences [0.001>P] in bacterial growth.
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Figure 24: Antimicrobial Activity Assay of LM7-1 against S.aureus. The graph
shows Optical density at 630 nm versus time for exposure in hours. The red bars show
the uninhibited growth of the bacteria. The remaining bars (orange, green, blue and
violet) show the amount of bacterial inhibition observed with increasing concentration
of peptide. The error bars display one standard deviation of variance. In the 24 hour
timepoint, compared to the uninhibited S.aureus growth (‡), only the 333 μg/ml
peptide trial shows an extremely significant (**) difference [0.001>P] in bacterial
growth.

The antimicrobial effectiveness of LM7-2 against the two gram negative
bacterial strains is shown: E.coli in Figure 25 and P.aeruginosa in Figure 26. In the
E.coli assay, all doses of the LM7-2 peptides were effective at inhibiting bacterial
growth at the 3 hour time point; only the two higher doses of the LM7-2 peptides
continued to inhibit bacterial growth at the 24 hour time point. In the P.aeruginosa
assay, no doses of the LM7-2 peptides significantly inhibited bacterial growth at the 3
hour time point; however, the two higher doses of the LM7-2 peptides significantly
inhibited bacterial growth at the 24 hour time point. The inconclusive results at the 3
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hour time point was likely due to the inherent background absorption of the yellowcolored peptide itself at high concentrations. This suggested that LM7-2 was active
against E.coli for the first few hours of incubation; however, LM7-2 was active against
both E.coli and P.aeruginosa at 24 hours post-treatment. This data suggested that
LM7-2 was broad spectrum effective against gram negative bacteria.

Figure 25: Antimicrobial Activity Assay of LM7-2 against E.coli. The graph
shows Optical density at 630 nm versus time for exposure in hours. The red bars show
the uninhibited growth of the bacteria. The remaining bars (orange, green, blue and
violet) show the amount of bacterial inhibition observed with increasing concentration
of peptide. The error bars display one standard deviation of variance. In the 24 hour
timepoint, compared to the uninhibited E.coli growth (‡), the 0.0333 μg/ml peptide
trial shows a significant (*) difference [0.05>P>0.001], and the 167/333 μg/ml peptide
trials show extremely significant (**) differences [0.001>P] in bacterial growth.
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Figure 26: Antimicrobial Activity Assay of LM7-2 against P.aeruginosa. The
graph shows Optical density at 630 nm versus time for exposure in hours. The red
bars show the uninhibited growth of the bacteria. The remaining bars (orange, green,
blue and violet) show the amount of bacterial inhibition observed with increasing
concentration of peptide. The error bars display one standard deviation of variance.
In the 24 hour timepoint, compared to the uninhibited P.aeruginosa growth (‡), the
0.0333/0.333 μg/ml peptide trials show significant (*) differences [0.05>P>0.001],
and the 167/333 μg/ml peptide trials show extremely significant (**) differences
[0.001>P] in bacterial growth.

The antimicrobial effectiveness of LM7-2 against the two gram positive strains is
shown: E.faecalis in Figure 27 and S.aureus in Figure 28. In the E.faecalis assay, the
two most concentrated samples of the LM7-2 peptides were effective at inhibiting
bacterial growth at the 3 hour time point; and continued to significantly inhibit
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bacterial growth at the 24 hour time point. In the S.aureus assay, the two higher doses
of the LM7-2 peptides inhibited bacterial growth at the 3 hour time point, and
continued to inhibit bacterial growth at the 24 hour time point. This data suggested
that LM7-2 was broadly effective against gram positive bacteria, at both early and late
stage post-treatment.

Figure 27: Antimicrobial Activity Assay of LM7-2 against E.faecalis. The graph
shows Optical density at 630 nm versus time for exposure in hours. The red bars show
the uninhibited growth of the bacteria. The remaining bars (orange, green, blue and
violet) show the amount of bacterial inhibition observed with increasing concentration
of peptide. The error bars display one standard deviation of variance. In the 24 hour
timepoint, compared to the uninhibited E.faecalis growth (‡), the 167/333 μg/ml
peptide trials show extremely significant (**) differences [0.001>P] in bacterial
growth.
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Figure 28: Antimicrobial Activity Assay of LM7-2 against S.aureus. The graph
shows Optical density at 630 nm versus time for exposure in hours. The red bars show
the uninhibited growth of the bacteria. The remaining bars (orange, green, blue and
violet) show the amount of bacterial inhibition observed with increasing concentration
of peptide. The error bars display one standard deviation of variance. In the 24 hour
timepoint, compared to the uninhibited S.aureus growth (‡), the 167/333 μg/ml peptide
trials show extremely significant (**) differences [0.001>P] in bacterial growth.

4.4.3 Minimum Inhibitory Concentration of LM7-1 and LM7-2
The Minimum Inhibitory Concentration (MIC) was defined by the Jia group as a
concentration of peptide sufficient to inhibit 50% bacterial growth for 24 hours as
compared to the uninhibited control (Jia et al, 2000). Figures 29-32 list the Dose
Response Comparison of LM7-1 and LM7-2 inhibition of growth for the 4 bacterial
species: E.coli in Figure 29, P.aeruginosa in Figure 30, E.faecalis in Figure 31, and
S.aureus in Figure 32. E.coli was the most susceptible bacteria, as it showed equal
vulnerability to both peptides, and had low MIC values. P.aeruginosa demonstrated
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strong resistance to LM7-1 and moderate resistance to LM7-2. E.faecalis was more
inhibited by LM7-2 than LM7-1. S.aureus was more strongly inhibited by LM7-2
than LM7-1.

Figure 29: E.coli Growth Inhibition at 24 hours versus Peptide Doses. The graph
shows 24 hours of bacterial growth monitored by Optical density at 630 nm versus
LM7-1 (blue line) and LM7-2 (green line) concentrations in mg peptide/ml total
culture volume. The error bars display one standard deviation of variance. Only the
0.000333 mg/ml doses of LM7-1 and LM7-2 are extremely significantly (**) different
from each other [0.001>P]. The MIC is 0.080 mg/ml for LM7-1, and 0.070 mg/ml for
LM7-2.
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Figure 30: P.aeruginosa Growth Inhibition at 24 hours versus Peptide Doses. The
graph shows 24 hours of bacterial growth monitored by Optical density at 630 nm
versus LM7-1 (blue line) and LM7-2 (green line) concentrations in mg peptide/ml
total culture volume. The error bars display one standard deviation of variance. The
0.0033 mg/ml the dose of LM7-1 and LM7-2 are significantly (*) different from each
other [0.05>P>0.001], and the 0.000333/0.167/0.333 mg/ml doses of LM7-1 and
LM7-2 are extremely significantly (**) different from each other [0.001>P]. The MIC
is >0.333 for LM7-1, and 0.130 mg/ml for LM7-2.

88

Figure 31: E.faecalis Growth Inhibition at 24 hours versus Peptide Doses. The
graph shows 24 hours of bacterial growth monitored by Optical density at 630 nm
versus LM7-1 (blue line) and LM7-2 (green line) concentrations in mg peptide/ml
total culture volume. The error bars display one standard deviation of variance. The
0.333 mg/ml doses of LM7-1 and LM7-2 are significantly (*) different from each
other [0.05>P>0.001], and the 0.000333/0.00333/0.167 mg/ml doses of LM7-1 and
LM7-2 are extremely significantly (**) different from each other [0.001>P]. The MIC
is 0.145 mg/ml for LM7-1, and 0.130 mg/ml for LM7-2.
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Figure 32: S.aureus Growth Inhibition at 24 hours versus Peptide Doses. The
graph shows 24 hours of bacterial growth monitored by Optical density at 630 nm
versus LM7-1 (blue line) and LM7-2 (green line) concentrations in mg peptide/ml
total culture volume. The error bars display one standard deviation of variance. The
0.333 mg/ml doses of LM7-1 and LM7-2 are significantly (*) different from each
other [0.05>P>0.001], and the 0.000333/0.00333 mg/ml doses of LM7-1 and LM7-2
are extremely significantly (**) different from each other [0.001>P]. The MIC is
0.305 mg/ml for LM7-1, and 0.165 mg/ml for LM7-2.

To calculate the MIC values for LM7-1 and LM7-2 against the four pathogenic
bacterial species, the maximum Optical density was divided in half, and the
corresponding peptide concentration was obtained from the dose response plotted
curves in Figures 29-32. Table 12 shows the MIC results, which indicate that LM7-2
(P-DER) was a more active peptide antibiotic than LM7-1 against most strains tested.
The lower the MIC, the more effective the AMP was at inhibiting bacterial growth
over a 24 hour period. Based on these results, LM7-1 was shown to be a
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therapeutically useful growth inhibitor for use against E.coli (MIC=80 μg/ml), and
E.faecalis (MIC=145 μg/ml). Based on these results, LM7-1 appeared to be largely
ineffective against P.aeruginosa (MIC>333 μg/ml), and S.aureus (MIC=305 μg/ml) in
cell culture assays. The LM7-2 sequence, although only different in one of its 27
amino acid residues, was shown to be therapeutically useful against E.coli (MIC=70
μg/ml), P.aeruginosa (MIC=130 μg/ml), E.faecalis (MIC=130 μg/ml), and S.aureus
(MIC=165 μg/ml). Overall,

LM7-2 was a more active, broad spectrum antimicrobial

peptide than LM7-1 was. Both chloramphenicol and NaOH trials were effective at
completely inhibiting bacterial growth of all 4 bacterial species over a 24 hour period.
Table 12: Minimum Inhibitory Concentrations (MICs) of LM7-1 and LM7-2.
The table lists concentration of LM7-1, and LM7-2 sufficient to inhibit 50% of
bacterial growth at 24 hours of incubation, as compared to the uninhibited control.

Peptide

LM7-1
LM7-2

Minimum Inhibitory Concentrations (MICs) in mg/ml
Gram (-)
Gram (-)
Gram (+)
Gram (+)
E.coli
P.aeruginosa E.faecalis
S.aureus
0.080±0.004
>0.333
0.145±0.007 0.305±0.007
0.070±0.009 0.130±0.015 0.130±0.026 0.165±0.012

4.4.4 Hemolysis Assay Discussion
A hemolytic assay is a method used to determine if useful therapeutic doses of
Antimicrobial peptides (AMPs) will potentially exert toxic effects by lysing human
red blood cells. Red blood cells are known to be sometimes vulnerable to cationic αhelical AMPs because their anionic cell membranes have many similarities to anionic
bacterial cell membranes. AMPs are considered too dangerous for use in humans if
they cause significant RBC lysis at or near therapeutic concentrations. As the
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membrane lipid compositions of red blood cells have been shown to vary widely
between mammalian species, it is more predictive to use human RBCs in hemolysis
assays rather than the more commonly used sheep RBCs.
4.4.4 Hemolysis Assay Results for LM7-1 and LM7-2
Human RBCs were collected from three anonymous volunteers at the URI student
health services laboratory, then washed and isolated. At high enough doses, Peptides
LM7-1 and LM7-2 caused hemolysis of human RBCs. The point at which a
concentration of peptides lysed 50% of the RBC at 1 hour into the assay was recorded
as the HC50 dose. Figure 33 indicated that LM7-1 was slightly more hemolytic than
LM7-2; however both caused lysis of RBC at very low concentrations.
The HC50 dose seemed to be unusually low, and is possibly due to inconsistencies
in the Hemolysis Assay itself. The method development for setting up this hemolysis
assay was difficult. The literature lists many varying and mutually inconsistent
methods of determining the HC50 dose. Many of the methods suggested scanning the
hemoglobin absorption at the 540 nm, which although conveniently in the visible
range, was wildly inconsistent depending on whether the hemoglobin was oxygenated
or not. Some doses of the peptide caused hemoglobin to visibly shift color from red to
red-brown, implying deoxygenation of the hemoglobin. The only hemoglobin
absorption peak that did not vary depending on oxygen concentrations was the 419 nm
peak. Another issue was that some of the concentrations of the positive control of
Triton X-100 suggested in the literature caused complete lysis of the RBCs as well as
hemoglobin degradation, which meant that 100% lysis did not necessarily equal
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maximum hemoglobin absorption. Other variables included spontaneous RBC lysis,
which anticoagulant was used during the collection process, the sample error using
only small volumes, and single replicate trials.

Hemoglobin Release of Human RBCs at 1 hour
versus Peptide Doses

Absorbance at 416 nm
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Figure 33: Dose Response Assay of LM7-1/LM7-2 Human RBC Hemolysis. The
graph displays absorbance at 419 nm (maximum hemoglobin absorbtion) of human
red blood cells incubated for 1 hour in PBS Buffer (pH 7.2, 4% RBC packed cell
volume) with the added LM7-1 peptide (blue line) or LM7-2 peptide (green line). The
graph shows released hemoglobin absorption at 419 nm versus peptide concentration
in μg peptide/ml total suspension volume. There was only one replicate per hemolysis
trial, so there are no error bars.
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Table 13 lists the exact HC50 values obtained in these experiments. The result
shows that although LM7-1 was active in inhibiting growth of 2 different types of
bacteria, and LM7-2 was active in inhibiting growth of 4 different types of bacteria,
both AMPs were too hemolytic to be therapeutically useful.
Table 13: Minimum Hemolytic Concentrations (HC50) of LM7-1 and LM7-2 at 1
hour. This table lists concentration of LM7-1 and LM7-2 sufficient to lyse 50%
human red blood cells (HC50) at 1 hour of incubation.

Peptide

LM7-1
LM7-2

Minimum Hemolytic Concentration
(HC50) in mg/ml
0.016
0.017
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CHAPTER 5
CONCLUSIONS
The design of alpha helical, amphipathic, antimicrobial peptides are
straightforward if the correct features are incorporated into the design, particularly
with the aid of in silico design tools. Based on primary literature research, the
following cationic, α-helical properties were important: an α-helix that only forms in a
membrane, the presence of a flexible hinge region, a polar face smaller than the
nonpolar face, C-terminal amidation to increase activity, a positively charged residue
in the middle of the nonpolar face to reduce aggregation/hemolysis, and a shortened
sequence to reduce chemical synthesis time and production expense. Although the
initial attempt at modifying an extant sequence only involved one amino acid change,
the major goal was to design more dramatic novel hybrids by mixing and matching
extant sequences to engineer the desired peptide properties. All of the novel
sequences were evaluated using in silico tests to predict physical properties, probable
effectiveness, and to eliminate unsuitable candidates for human therapeutic use. The
Edmonton Helical Wheel was used to predict the amphipathic profile for the AMPs,
the Chou-Fasman Algorithm was used to predict secondary structure, and the HoppWoods Hydrophilicity Scale was used to predict the transition zone between the Nterminal and C-terminal α–helical regions. These tools were initially used to evaluate
the P-DER hybrid AMP sequence. Attempts were made to tweak the sequence to
improve its antimicrobial activity without raising its hemolytic index. Then, using in
silico tools to incorporate the important features found in naturally-occurring, cationic,
α–helical AMPs, 20 novel hybrid AMPs were designed by mixing and matching
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segments of such active AMPs. Thus, the use of the in silico toolset was used to arrive
at the calculated data profiles used in generating novel, hybrid peptide sequences. The
prospective sequences were evaluated and narrowed down to 3 novel hybrid sequences
that conformed to the best calculated profiles of active AMPs. These sequences then
became designated hybrids LM7-3, LM7-4, and LM7-5.
The Solid Phase Peptide Synthesis (SPPS) for this project was completed manually
to monitor the challenges encountered in this type of synthesis so that the procedures
could be adjusted as necessary. These challenges included determining whether
certain Boc-amino acid types and locations within a particular sequence makes them
more difficult to attach to the peptide-resin than others. Refinement of the SPPS
technique and acquired experience led to greater coupling efficiency during the second
synthesis (LM7-2). During SPPS of LM7-1, 15 out of 27 residues required multiple
coupling attempts before succeeding. Peptide LM7-2 differed by one residue
(Lys15 → Gly15), but thanks to improved coupling strategies, only 7 out of 27 residues
required multiple coupling steps to succeed. Six of those multiple couplings were a
common problem sequence region in both LM7-1 and LM7-2, which implied that the
remaining extra coupling steps required to synthesize LM7-1 were more than likely
due to inexperience. The HF cleavage yielded a significant amount (>2g) of crude
AMPs for biological tests. Manual SPPS was laborious, so now that the difficult
sequences have been identified, any future related derivative sequences can be
synthesized on an automated peptide synthesizer that can run the coupling reactions
over many hours without extensive human intervention. Generally, as long as the
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peptide-resin sample is tested regularly with the ninhydrin test to confirm complete
coupling of every residue, automated SPPS is likely to be superior to manual SPPS.
The use of Gel Filtration was effective in removing gross impurities from the
peptide product, as the Sephedex beads separated the peptide sequences from the
much less massive reagent by-products and HF scavengers. Multiple runs were
needed to fine-tune the final LM7-1 purification, by developing an appropriate step
gradient protocol on the Preparatory Reversed Phase HPLC for the peptide.
Eventually, pure peptide peaks were reproducibly eluted from the column, and the
correct peptide masses were later confirmed with MALDI-TOF and LC-ESI mass
spectrometry. The established prep HPLC gradient was later also used to purify
related peptide LM7-2, as its hydrophobic properties were nearly identical to those of
LM7-1.
Molecular weight determinations by MALDI-TOF mass spectrometry, were then
used extensively during purification of LM7-1, to determine appropriate post-HPLC
peak pooling. However, when the INBRE lab switched to a more current MALDITOF machine, despite many hours of effort, the replacement unit failed to provide any
comparable data for LM7-2 peptide pooling. Therefore, it became a less precise
method of pooling peaks solely by HPLC elution times was used for LM7-2. Mass
spectroscopy using LC-ESI-MS confirmed the correct masses purified for LM7-1
(2913.638 Da) and LM7-2 (2984.675 Da); these measured values corresponded to the
calculated values obtained for the monoisotopic weights of the desired AA sequences.
The antimicrobial activity assay for significant inhibition of normal bacterial
growth for 24 hours post-treatment demonstrated a clear difference in antimicrobial
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activity between LM7-1 and LM7-2. LM7-1 was active against gram negative
bacteria, such as E.coli, but not against P.aeruginosa. LM7-1 was active against gram
positive bacteria such as E.faecalis, but less active against S.aureus. LM7-2 was more
active against gram negative E.coli, and P.aeruginosa than LM7-1. LM7-2 was more
active against gram positive E.faecalis and S.aureus than LM7-1. This data suggests
the alteration from (Lys15 → Gly15) lowered the AMP’s activity in a “broad spectrum
effect” simultaneously against all the bacterial species. A possible explanation for this
outcome was that the extra glycine made it more difficult for LM7-1 to form an alphahelical conformation at the bacterial cell membrane surface. Potentially, the additional
lysine positive charge was essential in targeting the AMP against all bacterial
membranes more effectively. Inhibitory activity was diminished against both gram
positive and gram negative species, so it is unlikely that subtle differences in cell wall
architecture between of the two classes of bacteria were the main issues in determining
the specificity of the peptides.
Although the protocol for the hemolytic assay is still in development, the
preliminary data suggested that the two peptides could both be highly hemolytic under
specific assay conditions, which limits their effective therapeutic doses. Human blood
was used instead of sheep’s blood as the red blood cells of the two species differ in
terms of cell membrane lipid structure. Due to the fact that all of the AMPs were
designed to be human therapeutics, it was necessary go through the extra
inconvenience to obtain fresh human RBCs. Although LM7-1 and LM7-2, when
tested, failed to clear the hemolysis test, it is still possible that repeating the hemolysis
assay using other types of animal blood cells might yield a better result. These AMPs
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could potentially be useful for veterinary applications even if they prove toxic to
humans.
The next three AMPs in this family, LM7-3, LM7-4 and LM7-5 have been
designed, synthesized and cleaved from the resin. In an extension of the current
project, they would be subjected to the same purification procedures, massed and
evaluated using antimicrobial and RBC hemolytic assays. In the future, the hemolysis
assays should be run well before the antimicrobial activity assays, as hemolytic AMPs
are useless as therapeutics due to the fact that the peptides would kill host RBCs
before inhibiting the growth of invading pathogenic bacteria. LM7-3 through LM7-5
could potentially display novel and useful biological effects, as they were designed
using in silico tools. The in silico tools allow multiple designs to be compared to
identify peptides candidates having the following desired properties: formation of an
α-helix/hinge/α-helix conformation in membranes, a partly amphipathic sequence, and
a gradual transition from a more hydrophilic N-terminal region to a more hydrophobic
C-terminal region. By using these criteria to rapidly narrow down prospective hybrid
peptides from distinct species of organisms with novel sequences, the best candidates
can be readily identified and screened for desired biological effects.
In sum, if properly employed, this hybrid approach to AMP design using novel
criteria to evaluate sequence modifications has great potential to unlock the power of
AMPs to treat drug-resistant bacterial infections. It is likely that sequence
modifications of known AMPs could be more effective against a wide variety of types
of bacteria, without simultaneously harming human RBCs via hemolysis. The natural
extension of this project is to evaluate via antimicrobial activity assays as well as
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hemolytic assays whether the novel hybrid peptides LM7-3, LM7-4 and LM7-5 can
distinguish between bacteria and RBCs better than LM7-1 and LM7-2 did. My
conclusion is that the incremental residue alteration made in LM7-1 may have
increased its hemolytic properties by disrupting essential sequence motifs that prevent
peptide self-aggregation. Using intact stretches of native AMP sequences to create
hybrid AMPs without disrupting essential residue patterns found within naturally
evolved sequences should increase antimicrobial activity and possibly reduce
hemolysis. AMPs have evolved for millions of years; retaining portions of the intact
sequences and recombining them is more likely to preserve their activities against
pathogenic bacteria, as opposed to single residue modification. The in silco design of
novel hybrid AMPs holds great potential for generating novel therapeutic effects, and
the improved understanding of poorly characterized sequence motifs encoded within
the native sequences of AMPs clearly requires new software tools and more
experimental data on what works to increase desirable features.
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APPENDIX A: ABBREVIATIONS
AMP: antimicrobial peptide
AMU: atomic mass units
Boc: tert-butyloxycarbonyl
CFU: colony forming units
Da: Daltons
DCC: N, N’-dicyclohexylcarbodiimide
DCM: dichloromethane
DCU: N, N’-dicyclohexylurea
DMF: N, N-dimethyl formamide
GUI: graphics user interface
HC50: minimum hemolytic concentration
HF: hydrofluoric acid
HBTU: 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
HOBt: 1-Hydroxybenzotriazole
LC-ESI-MS: liquid chromatography-electrospray ionization-mass spectrometry
LPS: lipopolysaccaride
MALDI-MS: matrix assisted laser desorption ionization - mass spectrometry
MBHA resin: 4-methyl benzhydrylamine styrene divinylbenzene copolymer
MIC: minimum inhibitory concentration
MW: molecular weight
OD: optical density
RP-HPLC: reversed phase high performance liquid chromatography
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SPPS: solid phase peptide synthesis
TFA: trifluoroacetic acid
TOF: time of flight
UV: ultraviolet
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APPENDIX B:
IN SILICO RESEARCH: ANTIMICROBIAL PEPTIDE EDITABLE
DATABASE (AMPED) PROJECT REPORT
B.1 Introduction
The AMPED project team was composed of: Lenore Martin, Project Manager and
Professor of Biochemistry; Daniel Ducharme, Computer Scientist and David Ryder,
Biochemist.
The primary rationale behind the AMPED project was to install an expert peptide
analysis system, possessing upgraded features as compared to existing peptide analysis
programs. A side goal was to develop collaborative relationships between scientists
and programmers. A desirable outcome was having the ability to generate a specific
database with searchable, stored fields along with expert peptide analysis systems that
were on par with if not better than the Peptide Companion® program (Lebl, 1992).
However, due to time constraints, only the expert systems were coded and the editable
database was set aside for a future project.
Peptide Companion®, is an old DOS program written for Windows 3.1 and used on
all of the operating systems since. This program was outlined as an exemplar as to
what features could be improved with the creation of the AMPED program; it has
many useful features, including an editable storage for sequences, and extensive tools
such as Chou-Fasman, HPLC prediction, Molecular weight and many other features.
However, the program has not been updated since 1992, and it cannot be modified. It

103

has never been updated for the newer operating systems, and has not been reissued
with the newer algorithms. Another issue with Peptide Companion® is that the
proprietary code means that the exact steps the algorithms take is unknown. For
example, the Peptide Companion® version of the Chou-Fasman algorithm only shows
the likelihood of forming various secondary structures as line graphs. The algorithm
was unable to evaluate the entire length of the peptide, and always skipped the last six
residues.
Peptide tools are an important element with peptide researchers looking for
accurate, complete and reliable information about the antimicrobial peptides of
interest. Along with sequence information, accurate, and well-documented
bioinformatic implementation of common algorithms is a vital component of a well
designed program. The AMPED expert system has the advantage of being open
source, as well as being transparent. All the algorithms used would be explicitly cited
and described in detail.
B.2 Problem Definition
The intention of the AMPED project was to create a database to hold data from a
variety of websites, and then designing tools to operate on that data. The toolset was
to be designed as open source using clearly published algorithms to allow for easy
validation of the tools. Each tool was to be tested by comparing it to both hand
calculated results and to the output of Peptide Companion®.
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The program was to be written in C++ since that was an strong language with a full
feature set and could interface with any database that was later chosen. At first the
database was decided to be programmed in MySQL because of its cross-platform
compatibility. However, due to graphic user interface (GUI) issues on Windows, the
program was switched to PostGreSQL which is also compatible with all major
operating systems but had a much better feature set for Windows.
The expert peptide analysis systems were geared to research groups that
synthesized, purified and assayed the effectiveness of Antimicrobial Peptides. The
most fundamental system needed was a peptide molecular average/monoisotopic
weight function. The raw data was obtained from the NIST Physics laboratory and
programmed in (NIST Website, 2010). In addition, the program was designed to
provide percentages of each amino acids within the sequence using simple string
searches and tabulations.
The second expert system was the use of the Chou-Fasman algorithm to determine
predicted protein secondary structure (Chou, 1978). It took a great deal of effort to
produce secondary structure predictions that reflected the Peptide Companion’s®
models. Once refinements were made, the results were judged to be at least equal to
the older program. It was decided that the step by step output of the Chou-Fasman
algorithm would be valuable to the peptide chemist, especially as concerning
questionable sequence assignments.
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B.3 AMPED Project Results
At this point both tools are operational and have their tabular data stored in the
database. The Amino Acid and Molecular Composition has been hand verified and
both the percent and molecular weight were confirmed to be correct. The AMPED
Chou-Fasman algorithm does correctly follow the published algorithm and enforces
parameters (such as having a minimum of five residues in a beta sheet) better than the
existing Peptide Companion® tool.

As currently designed, the Expert Systems on the AMPED program features:
1) Command Line Sequence input featuring manual or Copy/Paste input.
2) Peptide Analysis:
(a)

Predicted Molecular Weight (Monoisotopic or Average) can be
calculated.
(1)

(b)

In addition, it lists number/percent [x.xx] of each of the
following elements: (C/H/O/N/S/Cl).

Amino Acid Composition can be determined.
(1)

Program will Count number/percent [x.xx] of each of
the 20 standard amino acids.

3) Chou-Fasman Algorithm:
(a) Find all groups of 4 contiguous Alpha Helix formers with six
residues having an average Pa > 1.03.
(b) Extend each helix in both directions until the average Pa falls below
1.03 or a Proline is found not at the N-terminus end of the helix.
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(c) Find all groups of 3 contiguous Beta Sheet forming residues with
five residues having an average Pb > 1.00.
(d) Extend each sheet in both directions until the average Pb falls below
1.00.
(e) Find all groups of 4 residues that form a turn with an average Pt >
1.00 and a probability > 0.000075.
(f) Compare overlapping regions of Alpha and Beta and where Pa > Pb
mark as Alpha; otherwise mark as Beta.
(g) Test the length ensuring that each run still meets the requirements
of step a and c. If it fails the test, remove it. If the opposite
structure has been removed in step f, restore it and repeat step g.
B.4 Future Work and Conclusions
Although the AMPED program is functional, there are clear avenues for future
revision and expansion. There are many other expert peptide analysis systems that can
be added such as prediction of amino acids from molecular weight, helical wheel
projections and accounting for post-translational modifications to the sequence
(Schiffer, 1967). Another important layering is that of having a web-enabled GUI that
can be accessed by other research groups in order to use the database as well as its
peptide expert analysis systems. However, having these extra layers are only essential
if the output is a chart or drawing.
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In sum, the creation and collaboration required producing a functional and useful
Editable database that can further research goals, although challenging and complex, is
worthwhile.
B.5 Chou-Fasman Algorithm
1) α–helix formation:
(a) Read off the Pa values for 6 residues at a time. If 4 out of 6 residues
in a row average larger than 1.03, then an alpha helix can be nucleated.
A Proline residue can only be at the N-terminal end of the sequence.
(b) Extend until the average Pa value drops below 1.03. If the average
Pa is larger than Pb for the same stretch, then the region is an α–helix.
2) β–sheet formation:
(a) Read off the Pb values for 5 residues at a time. If 3 out of 5 residues
in a row average larger than 1.05, then a beta sheet can be nucleated.
(b) Extend until the average Pb value drops below 1.05. If the average
Pb is larger than Pa for the same stretch, then the region is a β–sheet.
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3) β–turn formation:
(a) Read off 4 residues in a row. If the Pt values average larger than
1.00, then a beta turn can be formed. If the average Pt for the stretch is
greater than the Pa or Pb values for the same sequence, then a beta turn
can form.
(b) To determine the precise start of the turn, find the products of fi,
fi+1, fi+2 and fi+3 for the residue of interest and each of the downstream
residues in sequence. If the product exceeds 7.5 x 10-5, then a good
initiation site for a beta-turn is assumed. The highest initiator with the
possible beta-turn stretch is nominally judged to be the first residue in
the turn.
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APPENDIX C:
MARTIN LAB STANDARD OPERATING PROCEDURES FOR CATIONIC
ALPHA HELICAL ANTIMICROBIAL PEPTIDE SYNTHESIS,
PURIFICATION, CHARACTERIZATION, AND ACTIVITY ASSESSMENT
C.1 Solid Phase Peptide Synthesis
C.1.1 Solid Phase Peptide Synthesis Procedure
1. Swell the methyloxybenzhydryl (MBHA) resin used for SPPS
dichloromethane overnight in dichloromethane (DCM), and assess the amount
of free amino groups using a quantitive ninhydrin test. This test will determine
how much of any given amino acid is needed to perform a coupling. For any
given coupling, use an excessive amount of the tert-butyloxycarbonyl (Boc)
amino acids in order to drive the reaction to completion.
2. Couple the first amino acid to the resin by using a Direct DCC catalyzed
1-hydroxybenzotriazole (HOBt) coupling protocol without the reagent
trifluoroacetic acid (TFA), using the Boc amino acid,
N, N’-dicyclohexylcarbodiimide (DCC), and HOBt. Check if the reaction has
been completed by performing a ninhydrin test. If it has coupled, proceed to
the next residue; if it hasn’t, switch to a different coupling protocol. There are
many different protocols available to couple Boc amino acids to growing
peptide chains. A sample order is the Preformed Symmetric Anhydride
Protocol, Direct DCC Catalyzed Coupling Protocol, and Direct HBTU
Catalyzed Coupling Protocol.
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3. Any subsequent Boc amino acid residues should be coupled and if a ninhydrin
check proves positive, switch to a different protocol until the Boc amino acid is
fully coupled. A useful order is Direct DCC Catalyzed Coupling Protocol,
Preformed Symmetric Anhydride Protocol, Direct DCC catalyzed HOBt, and
Direct HBTU Catalyzed Coupling Protocol.
4. Once the synthesis is complete, the peptide-resin can have the histidine side
groups deprotected; then the sequence can be cleaved with hydrofluoric acid,
and characterized.
C.1.2 Solid Phase Peptite Synthesis Coupling Protocols
Protocol #1: Direct N, N’-dicyclohexylcarbodiimide Coupling Protocol after acid
deprotection of the amino acid group of the growing chain with trifluoroacetic
acid
1. Make sure the resin is fully swollen in DCM solvent solution in a glass
reaction vessel (RV) fitted with a fritted filter prior to coupling. The frit
prevents the solid phase resin from escaping when the reagents are drained out
of the RV. The reaction vessel should be mounted on a shaker to ensure
complete mixing. Wash with DCM three times, and completely drain the RV
of wash solvent after each wash step.
2. Add a solution of 50% TFA/50% DCM, with a volume sufficient to fully
suspend the peptide resin and let the reaction vessel shake for 90 seconds, to
allow the resin to swell up to its maximum volume in this reagent. Drain off
the TFA/DCM mixture and add a fresh amount of the acid deprotecting
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reagent. Allow the reaction vessel to shake for 90 minutes to ensure the TFA
solution completely cleaves off all the Boc protecting groups, and then drain
off the excess reagent. Warning: this step is when the RV is most likely to leak
through the threads of its Teflon cap. TFA is also a volatile, dangerous acid; it
presents both a contact and inhalation hazard. Neutralize all TFA after use.
3. Wash the resin thoroughly with six washes of DCM, followed by two 90second washes of the basic solution (20% diisopropylethylamine (DIEA)/80%
DCM) to neutralize any residual TFA, as well as to restore the ionized amine
salts back to a reactive, deprotonated, “free-base” form. Complete the series of
post-Boc deprotection with six more rounds of DCM washes.
4. Weigh out a five equivalents of the Boc-amino acid and dissolve the protected
amino acids in a minimal amount of DMF; then and add the solution to the
reaction vessel. Do not drain.
5. Measure out volumetrically, a five equivalents of DCC in a calibrated ~0.50 M
stock solution prepared fresh in DCM. Add the solution to the RV, but do not
drain.
6. Add sufficient additional DCM to fully suspend the resin, Boc-amino acid and
coupling reagent and start the shaker to couple for at least 90 minutes. After
90 minutes, the reaction should be completed; using an aspirator vacuum, drain
out the leftover reagents and solvent.
7. Do four post-coupling resin washes with DCM, followed by two 90-second
washes with 10% DIEA/90% DCM, and finally six more washes with DCM.
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Leave the peptide-resin fully suspended, swollen, and shaking in solvent after
the final wash until the next procedure is begun.
8. Perform a ninhydrin check to verify that all the free amino groups on the resinbound growing chains have reacted completely with the incoming Boc amino
acid. Repeat the coupling reaction with the same Boc-amino acid if the
ninhydrin test is positive, or go onto coupling the next amino acid in the
sequence if the ninhydrin test is negative.
Protocol #2: Preformed Symmetric Anhydride Coupling Protocol without
without prior trifluoroacetic acid deprotection of the amino group
1. Fully swell the peptide resin in DCM prior to performing any coupling step to
expose the maximum number of peptide chains to the coupling reagents as
possible. Wash with a DCM solution three times to initiate the procedure, and
fully drain the RV after each wash.
2. Weigh out a two equivalents of the Boc amino acid to be coupled, with the
amount of free amine groups on the growing peptide chains attached to the
solid phase resin. Dissolve the Boc-AA in a minimal amount of DMF in a
small, dry, glass Erlenmeyer flask Measure out volumetrically, 1 equivalent of
DCC in a calibrated ~0.50 M stock solution prepared fresh in DCM. Add the
DCC solution to the flask to allow the DCC to catalyze coupling of the Boc
amino acid to itself, which produces the reactive, preformed symmetrical
anhydride of the incoming Boc-amino acid. After allowing the reaction to
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proceed for 5-10 minutes, add the symmetric anhydride solution to the RV, but
do not drain.
3. Add sufficient additional DCM to fully suspend the resin, the activated
preformed symmetrical anhydride of the Boc-amino acid and coupling reagent,
then start the shaker to couple for at least 60 minutes. After the reaction
completes, use an aspirator vacuum to drain out the leftover reagents and
solvent.
4. Do four post-coupling resin washes with DCM, followed by two 90-second
washes with 10% DIEA/90% DCM, and finally four more washes with DCM.
Leave the peptide-resin fully suspended, swollen, and shaking in solvent after
the final wash until the next procedure is begun.
5. Perform a ninhydrin check to verify that all the free amino groups on the resinbound growing chains have reacted completely with the incoming Boc amino
acid. Repeat the coupling reaction with the same Boc-amino acid if the
ninhydrin test is positive, or go onto coupling the next amino acid in the
sequence if the ninhydrin test is negative.
Protocol #3: Direct 1-hydroxybenzotriazole Coupling Protocol without prior
trifluoroacetic acid deprotection of the amino group
1. Fully swell the peptide resin in DCM prior to performing any coupling step to
expose the maximum number of peptide chains to the coupling reagents as
possible. Wash with a DCM solution three times to initiate the procedure, and
fully drain the RV after each wash.
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2. Weigh out four equivalents of the Boc amino acid to be coupled. Equivalents
are calculated as the amount of free amino groups at the ends of the growing
peptide chains attached via their C-terminal ends onto the MBHA resin.
Weigh out four equivalents of the racemization suppressor, HOBt. Dissolve
the coupling reagents together in a minimal amount of dimethylformamide
(DMF) solvent and add the mixture to the reaction vessel. Mix, but do not
drain.
3. Volumetrically measure out four equivalents of a calibrated DCC solution in
DCM and add it to the reaction vessel. Be careful to avoid skin contact, as
DCC is an extremely strong allergen. Mix, but do not drain.
4. Add sufficient additional DCM to just barely suspend the resin and reagents so
they mix efficiently in the RV, and then start the shaker, and allow the first
coupling reaction to proceed at RT for at least 90 minutes. After the reaction is
complete use a vacuum to filter out the leftover coupling reagents with a water
aspirator trap.
5. Following each coupling reaction, use four washes of each of the following
reagents: DCM, DMF, methanol, and again DCM. This will ensure that
residual reagents and soluble by products are eliminated, leaving only the resin
and its attached amino acid chains behind.
6. Perform a ninhydrin check to verify that all the free amino groups on the resinbound growing chains have reacted completely with the incoming Boc amino
acid. Repeat the coupling reaction with the same Boc-amino acid if the
ninhydrin test is positive (any degree of blue coloration is observed), or go
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onto coupling the next amino acid in the sequence if the ninhydrin test is
negative (pure yellow solution).
Protocol #4: Direct 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU) Coupling Protocol without prior trifluoroacetic
acid deprotection of the Boc group on the amino acid
1. Swell the peptide resin in DCM prior to coupling to expose the maximum
number of peptide chains possible. Wash with DCM four times, and drain the
reaction vessel after each wash.
2. Weigh out a five equivalents of the Boc amino acid. Dissolve the Boc-amino
acid in a minimal amount of DMF in a small, dry, glass Erlenmeyer flask
Weigh out five equivalents of HBTU and add it in to the same mixture,
followed by a ten equivalents of 20% DIEA/80% DCM to activate the HBTU.
Pour the mixture into the reaction vessel.
3. Add sufficient DCM to suspend the resin and reagents and start the shaker for
at least 60 minutes. After the reaction is complete, drain out the leftover
reagents using vacuum filtration.
4. Do four resin washes of DCM, followed by two 90 second washes of 10%
DIEA/90% DCM, and finally four washes of DCM. Leave the peptide-resin
suspended and shaking after the final wash.
5. Perform a ninhydrin check to verify if all the free amino groups on the resin
have reacted with the Boc amino acid. Repeat the next coupling if the
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ninhydrin is positive, or proceed to the next amino acid coupling if the
ninhydrin is negative.
C.1.3 Ninhydrin Free Amine Verification
1. The ninhydrin test is used to indicate the presence of free amine groups; either
on SPPS resin directly, or on attached, N-terminal unprotected peptides bound
to the resin. This particular test uses a combination of three reactive reagents
to perform the test. Ninhydrin forms a blue, light absorbing complex with the
amine group, KCN serves as a reducing agent, and pyridine displaces
ninhydrin from the resin so the ninhydrin can enter the solution and be detected
with a spectrophotometer.
2. Nihydrin uses two solutions, labeled Reagent A and B. To make Reagent A,
40 g of phenol is added to 10 ml of absolute ethanol and gently heated to
dissolve the phenol. Add, stir, and filter out 4 g of MB-3 Amberlite® resin. In
a separate flask, dissolve 65 mg of KCN in 100 ml of water. Remove a 2 ml
aliquot, and dilute it to 100 ml using pyridine. Add, stir and filter out 4 g of
MB-3 Amberlite resin. Combine the phenol and KCN/pyridine solutions. To
make Reagent B, dissolve 2.5 g of ninhydrin in 50 ml of absolute ethanol, and
store it under nitrogen.
3. Take out a 2-5 mg sample of peptide/resin and place it into a small tube. Add
4 drops of ninhydrin Reagent A, and 2 drops of ninhydrin reagent B to the
sample tube and to an empty control tube. Place the sample tubes in a block
heater set to 100ºC for exactly 10 minutes to allow the reaction to complete.

117

4. Take out the sample tubes, allow them to cool, and then add some isopropanol
and agitate the tubes to thoroughly mix the contents. Any pure yellow color in
the liquid is the natural color of the unreacted ninhydrin reagents and is
interpreted as a negative result. Any reaction of free amines to the reagents
will add a blue color to the sample. The more intense the color is, the more
free amine groups are in the sample.
5. If an exact quantification of free amine groups is required, filter the sample
with 60% ethanol through a glass pipette stuffed with glass wool, and dilute it
out to 10.0 ml in a volumetric flask. Place the sample in a quartz cuvette in a
spectrophotometer set to 570 nm to detect the absorption of the blue pigment.
The concentration will be proportional to the absorbance.
C.1.4 Histidine-dinitrophenol Removal Protocol
1. This protocol is used to remove the dinitrophenol (DNP) side chain protection
from histidine. Swell the Boc-protected peptide resin in DMF for several
minutes in a glass solid phase reaction vessel. Drain the DMF. Add fresh
DMF at a ratio of 5 ml DMF per gram of peptide-resin.
2. Without draining the solvent, add 20 mmol thiophenol (0.102 ml/mmol, or 2
ml) for each mmol of His (DNP) present in the product peptide. Stir (or shake)
the mixture for four hours at room temperature. The solution should turn bright
yellow as DNP is removed.
3. Drain thoroughly, and wash the resin three times with (DMF) and
dichloromethane (DCM), followed by four washes of 1:1 Methanol/DCM and
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DCM. A small amount of intensely yellow colored DNP-thiophenol may
remain adsorbed to the peptide-resin. After standard wash procedures, the
peptide-resin may still be slightly yellow, but the sulfurous odor should be
completely gone. The used thiophenol solution, and any apparatus that
touched it should be immersed in a 10% bleach solution and stored in the hood
until the smell is dispersed.
4. Remove the N-terminal Boc group with 50% TFA in DCM before the HF
Cleavage.
C.1.5 Anhydrous High Hydrofluoric Acid Cleavage Protocol
1. At the end of SPPS, immediately prior to the peptide-cleavage step, the Nterminal Boc protecting group should be removed using 50% TFA in DCM
followed by a ninhydrin test to confirm free amine groups are exposed. It is
also used to verify the amount of free N-terminal amine that is present on the
peptide-resin product.
2. Dry the deprotected peptide-resin by washing with DCM several times and
then vacuum filter it until it is dry and flaky. Then transfer up to 1.0 g peptideresin into each of the two Kel-F® HF cleavage vessels followed by a tefloncoated stir bar. Add the bumper lids with the o-ring ridges facing up. Cover
the lids with parafilm and poke holes to allow vapors to escape. Place the HF
vials upright in a vacuum flask and lyophilize the peptide-resin samples at
room temperature overnight.
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3. Break the vacuum, remove the HF vials containing the dry peptide-resin, and
add HF scavengers. For a typical peptide, use a cleavage mixture of 10:1:1
HF/p-cresol/p-thio cresol (v/v/v). Plan for 5 ml of HF for every 0.5 g of
peptide-resin mass. WARNING: hydrofluoric acid (HF) is extremely toxic and
can cause bone damage if it absorbed through the skin. Keep a 26% MgSO4
solution on hand to soak and wash affected areas; also have a calcium
gluconate gel to apply topically or inject on the burn site to neutralize the acid.
Seek medical attention at once if you suspect you have been burned.
4. Check the KOH trap to make sure it contains adequate base to neutralize any
excess HF. The phenolphthalein dye indicator should be orange (pH >8).
Leak test the HF apparatus using N2 gas after mounting the peptide-resin (RV)
reaction vessel(s) to ensure the system is closed. Chill the HF vials to -78ºC in
vacuum dewer flasks using an isopropanol slurry, and dry ice for at least 20
minutes before attempting to distill HF into the vessels. Once HF is distilled
into the cleavage flask, the peptide-resin should turn red.
5. Once HF is delivering properly through the system, monitor the volume of HF
condensed into each RV by lowering the jacks supporting the dewars and
holding a flashlight behind the RV so the HF level may be observed. If the
correct volume of liquefied HF is present, stop the HF flow, flush the system
with N2 gas, and begin stirring the HF vessels vigorously, maintaining the HF
vessels temperature at 0°C with an ice-water mixture for 1 hour.
6. After 1 hour at 0°C, carefully open the 3-way valves on the apparatus so the N2
gas blows the HF into the KOH trap at a rate that does not “bump” the resin up
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into the apparatus. N2 gas is used to drive out HF and dry the peptides and
resin, one vessel at a time. When all the HF has been removed, use the water
aspirator system to completely dry out the resin vessels and apparatus.
7. Unscrew the HF vessels containing resin, scavengers, and product peptide
from the apparatus. Extract the scavengers from the peptide and resin with
diethyl ether twice; then extract the peptide from the resin using 10% aqueous
acetic acid (v/v). The acetic acid will dissolve the peptide and the solution can
be filtered, separating out the solubilized peptide solution from the insoluble
resin beads. Follow with “safety extracts” using glacial acetic acid, in case the
peptide is very insoluble, then dry and set aside the resin as waste. Lyophilize
the 10% and glacial acetic acid extracts and determine the yield of crude
peptide obtained.
C.2 Liquid Chromatography Purification
C.2.1 Gel Filtration Liquid Chromatography with a G25 Sephedex Column
1. Sephedex® is a dextran derived, cross-linked mixture of polysaccharide beads
that are manufactured at varying pore sizes to exclude all analytes above a
certain cutoff mass; all substances below the cutoff are retained in inverse
proportion to the overall mass. For most peptides, using this compound after
Solid Phase Peptide Synthesis will separate the large peptides from the low
mass synthesis byproducts.
2. The column using the Sephedex® must use size G25 at the most, otherwise the
5 kDa peptide will be retained by the beads. Any mixture of G15, G10 can be
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used with G25 as long as the beads are thoroughly mixed. The beads should
be always kept wet in a 10% aqueous acetic acid (v/v), which can be added via
a peristaltic pump from a reservoir.
3. The drain line from the column should be routed through a flow cell in a UV
absorbance detector set to 280 nm to note tryptophan absorbance as the peaks
elute. If the peptide does not contain tryptophan, 220 nm can detect the
absorbance of the peptide bonds themselves. The eluent should be deposited
into fraction tubes so that the peptide product peak can be isolated from the
synthesis byproduct peak. The UV detector should be connected to a chart
recorder to provide a chromatogram for the run.
4. Ensure the Void volume is known by running blue dextran solution through the
column and measure how much liquid is collected before the dye elutes. Blue
dextran is a massive polysaccharide that will be larger than the cutoff size for
any type of gel filtration bead.
5. Dissolve the crude peptide so the concentration is roughly 25 mg peptide/ml of
10% v/v acetic acid. The solution must be refrigerated at 4ºC to slow any
peptide degradation.
6. Let the column drain down to just the top of the Sephedex bed and layer the
sample evenly across the top. The size of the applied sample will vary
depending on the column specifications. A 3 cm diameter column will
accommodate a 3-5 ml sample volume. A 9 cm diameter column can handle
the entire volume of a 2 g crude peptide extract from a small scale SPPS
synthesis in a single run.
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7. Let the sample drain down to the top of the Sephedex bed and establish a head
space of 10% acetic acid atop the bed.
8. Start the peristaltic pump and let the eluent flow through the UV detector and
pool the liquid until the void volume is reached; all of the liquid collected up to
that point will be waste. The second void volume should be the primary
peptide, followed closely by failed sequences that are slightly less massive
than the desired sequence due to missing amino acid residues. The third void
volume will be leftover synthesis reactants and the scavengers left over from
the hydrofluoric acid cleavage.
9. Due to the concentrated nature of the crude peptide sample, the absorbance in
the flow cell UV detector will maximize at the upper end of the detection range
and plateau out until most of the sample has eluted.
10. After collection has stopped, the fraction tubes can be processed by running
them individually in a spectrophotometer at 280 nm (or 220 nm) to determine
the true absorbance values where the sample is the most concentrated. 1/10
dilutions can be used if the absorbance of the neat samples are too high.
11. Once the absolute absorbance values are known, use them to determine the
time from where the first peak starts to elute to where the absorbance starts to
rapidly fall. This range will contain the purest amount of desired product. Pool
everything within that range and label it the ‘A’ Peak. Everything after that to
where the absorbance falls back down to baseline levels will mostly contain
worthless products; this can be labeled the ‘B’ Peak and pooled.
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12. Freeze the samples in Lyophilizer flasks by inserting them into an isopropanol
solution chilled to -80°C using dry ice. Rotate the flasks to coat the sides with
a thin, frozen film of acetic acid and product. Place the flasks in shallow pans
filled with an isopropanol/dry ice mixture, connect the flasks to the lyophilizer
and freeze dry the samples under vacuum to sublime off the frozen acetic acid.
The crude product can then be subject to characterization by analytical HPLC
and processed in bulk by preparatory HPLC.
C.2.2 Preparatory Reversed Phase High Performance Liquid Chromatography
with a C18 Column
1. The peptide mixtures should be dissolved prior to HPLC analysis or
purification in 10% acetic acid, ensuring that the concentration is no higher
than 10 mg peptide/ml. The analyte solution should be refrigerated at 4ºC to
slow down any peptide degradation until it is lyophilized to dryness. Just prior
to a RP-HPLC run, inject up to 5 ml of the sample into the sample loop.
2. Run the 5% acetonitrile/95% water/0.1% TFA mobile phase through the
column until the baseline absorbance on the UV detector stabilizes. Zero out
the detector and start the run by switching the valve to inject the loaded peptide
product in the sample loop. For step gradient runs, change out the reservoir
bottles every time a higher concentration of acetonitrile is required. Make sure
to mark on the chromatogram exactly when each new mobile phase
concentration begins. At the end of the run, in order to the flush the column
free of any residual products; the highest concentration of mobile phase used
should always be set to 95% acetonitrile/5% water/0.1% TFA and run until the
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absorbance reaches the baseline level. Test runs with small amounts of peptide
can be used to develop a gradient method capable of achieving baseline
separated peaks for each new peptide sequence.
3. After elution has stopped, process the eluent fraction tubes into sub-groups
representing three distinct zones: baseline absorbance outside of peaks, the first
five fractions of a peak, and the tail end of a peak. Baseline absorbance zones
will not usually contain any usable peptide, the leading edges and peak regions
will have products of the highest purity, and the tailing edges will contain
impure products. One way to assign peaks is to start with the prep column run
code followed by letter indicating the order in which each peak eluted during a
run. For example, label 4C can refer to the third peak on the forth prep run.
Concentrate pooled fractions on a Rotovap® until all the acetonitrile is
removed, and then place the samples into 15 or 50 ml plastic centrifuge tubes.
4. Freeze the pooled and purified samples in centrifuge tubes by inserting them
into an isopropanol slurry. Rotate the tubes to coat the sides of the tubes with a
thin, frozen film of sample. Use a thumbtack to poke pinholes in the plastic
caps to allow the vapor to escape during lyophilization. Place the tubes inside
lyophilizer flasks, and then cool the flasks in shallow pans filled with an
isopropanol/dry ice slurry. Afterwards, connect the flasks to the lyophilizer to
freeze dry the samples under vacuum to sublime off the acetic acid. The
pooled fractions are characterized by MALDI-TOF mass spectroscopy to
determine if they contain the peptide of interest.
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C.3 Mass Spectroscopy
C.3.1 Matrix Assisted Laser Desorption Ionization-Time of Flight
1. Prepare a sample of 2 ug/ml of a known mass standard used to calibrate the
MALDI-TOF. Dissolve single crystals of dried peptides in 35 μl of 10% v/v
acetic acid. Make tenfold dilutions of the samples using a diluent mixture
(50% acetonitrile/49.95% water/0.05% TFA). Spot the sample plate with 1 μl
of 10 mg sinapic acid dissolved in the same diluent to make up the sample
matrix; then pipet 1 μl of the peptides samples on a metal chip within the
center of the matrix droplets, and let the samples dry thoroughly.
2. Place the chip in the MALDI-TOF sample holder and expose it to high vacuum
conditions. Scan the MW standard first and correct any deviations from its
known mass; this serves to calibrate the machine to accurately record
charge/mass ratios for all the other samples.
3. Scan the rest of the samples with the laser beam and save the detector results.
Label the relevant peaks. Pure samples will typically only have one welldefined peak of the desired mass. Impure samples will have multiple peaks.
4. Use the determined charge/mass values to pool the peptide samples across
multiple RP-HPLC runs into appropriate fractions of the synthetic peptide.
Pure samples can be used directly for antimicrobial testing. Other samples can
be re-purified if more product is needed at a later date.
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C.3.2 Liquid Chromatography-Electrospray Ionization-Mass Spectroscopy
1. Dissolve single crystals of dried peptides in 20 μl of HPLC Buffer A (50%
acetonitrile/49.95% water/0.05% formic acid). Inject 1 μl of the dissolved
peptides samples into the LC column.
2. Note the results in terms of Retention Peaks, Total Ion Chromatograms, and
Selected Ion Chromatograms. This information is used to determine m/z ratios
for various charges (+1, +2, etc). The m/z ratios can be deconvoluted to
determine the overall mass of the uncharged compound.
3. If no major peaks are found, repeat steps 1 and 2 with a 10 μl injection to
increase peptide sample amounts.
C.4 Antimicrobial Assays
C.4.1 Antimicrobial 96-Well Plate Activity Assay
1. Soak any contaminated glassware must overnight in an equal volume of 6%
bleach solution, to kill all microorganisms. Wash with soap and water and let
them air dry.
2. Use Mueller-Hinton agar for plates, Nutrient agar for slants, and MuellerHinton media for broth. Set up broth cultures from slants by disinfecting the
work surface with 70% isopropanol. Then set up 4 slant cultures: Esherichia
coli, Enterococcus faecalis, Staphylococcus aureus, and Pseudomonas
aeruginosa. Transfer sterilized broth media to 150 ml Erlenmeyer flasks. Add
a loopful of slant growth to the matching labeled flask. Always do
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Staphylococcus aureus last as it is easy to cross-contaminate other cultures
with it. Place flask overnight in 37°C incubator shaking at 200 RPM.
3. Set up the subcultures by disinfecting the work surface with 70% isopropanol.
Next, set up 4 broth cultures: Esherichia coli, Enterococcus faecalis,
Staphylococcus aureus, and Pseudomonas aeruginosa. Transfer sterilized
broth media to 150 ml Erlenmeyer flasks. Add a loopfull of broth growth to
the matching labeled flask. Always inoculate Staphylococcus aureus last.
Place flask overnight in 37°C incubator shaking at 200 RPM; repeat the
procedure if necessary.
4. Determine optical density (OD) by turning on a Spec20 spectrophotometer and
let it warm up for 30 minutes. Adjust the wavelength knob until the reading is
for 630 nm. Set the left (% Transmittance) knob to 0%, and then insert a
Mueller-Hinton blank, and turn the right (Absorbance) knob to 0. Read the
samples by placing 3 ml of the sample into a 1x10 cm tube, vortex it, and
insert it into the spectrophotometer.
5. Adjust the optical density to ensure logarithmic growth for the bacterial
culture; the best value is an OD630 of 0.120. If the OD is too high, dilute it
down with sterilized Muller-Hinton broth to 1/2, 1/5, and 1/10 dilutions until it
is around 0.120. Once the OD is reasonable, use the following equations to set
up the amount of bacterial broth to use, then measure the diluted OD:
(5 ml) (0.120/Determined OD) = x (Volume of bacterial broth)
(5 ml – x) = Amount of Muller-Hinton broth to add
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(1)
(2)

6. Suspend the AMP in solution of Hancock Diluent to make a working
concentration of 5 mg/ml. Take an aliquot from this sample to make a 1:10
dilution, and do a second serial dilution to 1:100. Set up the chemical
antibiotic so its working concentration is 0.1 mg/ml. Set up sterile 8-well
broth trays. Use at least 5 ml of the bacterial suspension as well as 10 ml of
Muller-Hinton broth. Use the first 3 rows for Muller-Hinton broth, skip a row,
and use the next 3 rows for the diluted bacterial broth. Set up the 8-arm
mulipipetter for 150 μl aliquots. Apply even pressure to properly seat the tips.
7. Set up the 96-well plate. Each well can accommodate 300 μl of liquid. The
plate has 8 rows which give 8 replicate results for each column. There are 12
separate columns for different conditions. The conditions are as follows:
Media (Mueller-Hinton broth only), Bac (Esherichia coli, Enterococcus
faecalis, Staphylococcus aureus, or Pseudomonas aeruginosa), Dil (Dilution),
AMP, Antibio (active antibiotic), 6 M NaOH (total cell kill solution).
8. Make sure all the wells contain 300 μl of volume. Fill up the wells in the 96well plate. Columns 2-6, 8-9, and 11 get 150 μl of the bacterial broth. For the
Mueller-Hinton media: column 3 gets 130 μl, columns 4/8/9 get 140 μl, and
columns 1/7/10 get 300 μl. Add 20 μl of the neat AMP solution to Column 3,
and 10 ul to column 4. Add 2 ul of the 1:10 AMP dilution to column 5 and 2
ul of the 1:100 AMP dilution to column 6. Add 10 μl of 6M NaOH to column
9 as ‘kill’ conditions. 10 μl of the antibiotic is added to column 8.
9. Use the 96-well plate reader by turning on the device, and the attached
computer. Make sure the SoftMax Pro® or an equivalent program is running
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and ready to collect data. Set up wavelength to 630 nm, insert the plate into
reader, and take a measurement. In between measurements, store the plates on
a shake platform at 37°C. Take a reading every half hour for 3 hours, and then
after the plate has incubated overnight. Save files as X-PDA format (Softmax
only) or open source/ASCII X.csv/x.txt format that can be imported into any
analytical software.
C.4.2 Procedure for Antimicrobial peptide Hemolytic Assay Protocol
1. To follow Biohazard protocol, soak any contaminated glassware overnight in
6% bleach solution, to kill all microorganisms. Wash with soap and water and
let them air dry. Any blood contaminated sharps must be placed in a properly
marked Biohazard container for disposal.
2. Draw whole human blood samples into 3.5 ml tubes containing an
anticoagulant, such as Heparin, to prevent blood clot formation, and to
facilitate intact red blood cell isolation. Gently mix the samples, spin them
down at 800 x g, and wash them several times with filter-sterilized PBS Buffer
(100 mM NaCl, 80 mM Na2HPO4, 20 mM NaH2PO4, pH 7.4) until the
supernatant becomes clear. Dilute the washed RBCs with PBS Buffer to a
final concentration of 8% (v/v).
3. One type of Hemolysis Assay uses a total of five peptide dilutions. The stock
peptide concentrations would be 5 mg/ml (1.71 mM) for LM7-1 and 5 mg/ml
(1.67 mM) for LM7-2. Tubes 1-3 get 150 μl of the 8% (v/v) RBC suspension,
and Tubes 4-5 get 750 μl. For the AMP solution: Tube 1 (50 μl), Tube 2 (40
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μl), Tube 3 (20 μl), Tube 4 (10 μl), and Tube 5 (1 ul). For the PBS Buffer
solution: Tube 1 (100 μl), Tube 2 (110 μl), Tube 3 (130 μl), Tube 4 (740 μl),
and Tube 5 (749 ul).
4. After making up the assay tubes, make a positive hemolysis control with 750
μl of RBC and 750 μl of 0.020% aqueous Triton X-100 solution to osmotically
lyse the RBCs. Make a negative hemolysis control with 750 μl of RBC and
750 μl of PBS buffer to ensure that the buffer does not damage the cells during
the course of the assay. Incubate the samples with constant, gentle agitation at
37ºC. At selected time points, up to 24 hours, centrifuge a 60 μl aliquot of
each sample at 4000 x g for 10 minutes to pellet the intact RBCs. Withdraw 50
μl of the sample supernatant and pipet it into 450 μl of PBS Buffer to dilute the
sample tenfold.
5. Use the Genesys 10UV Scanning UV-VIS spectrophotometer by turning on the
device. Allow the bulb to warm up for 30 minutes. Insert a quartz cuvette
containing PBS buffer into the device and blank the scan. Scan the samples at
419 nm which is the tallest absorbance peak found in soluble hemoglobin.
Calculate percent hemolysis using the formula below:
% Hemolysis = [(AbsPeptide – AbsPBS)/(Abs0.020% Triton X-100 – AbsPBS)] x 100 (1)
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